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Current antipsychotic drugs act on dopamine (DA) D2 receptors for their therapeutic 
effects, but their limitations have driven a search for novel treatments. Pharmaceutical research is 
generally performed in normal rats, whereas models that account for variables including disease-
relevant pathophysiology may improve predictive validity. D2 antagonists have been shown to 
reduce DA neuron activity via D2 autoreceptors to produce over-excitation induced cessation of 
cell firing (depolarization block). Aripiprazole is a D2 partial agonist shown to normalize 
hypodopaminergic and hyperdopaminergic states, but through unclear mechanisms. The 
methylazoxymethanol acetate (MAM) model was used to observe aripiprazole’s effects on 
hyperdopaminergic activity, compared to control (SAL) rats, using in vivo, anesthetized, 
electrophysiological recordings. Aripiprazole had no effect in controls, but reduced 
hyperdopaminergic activity in MAM rats, which was not reversed by apomorphine, suggesting a 
mechanism other than depolarization block.  Furthermore, aripiprazole removed D2 antagonist-
induced depolarization block in MAM rats, consistent with autoreceptor agonism, potentially 
explaining its downregulation of hyperdopaminenrgic activity. These results demonstrate state-
dependent neuropharmacological effects. Group II metabotropic glutamate receptors (mGluR2/3) 
showed promise as a novel target in preclinical research, but the mGluR2/3 agonist, pomaglumetad 
methionil (POM), showed insufficient efficacy in clinical trials. Although previous studies have 
shown that mGluR2/3 agonists have no effect on DA in normal rats, MAM rats were used to 
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determine whether POM normalizes a hyperdopaminergic state.  POM dose-dependently reduced 
DA neuron activity of MAM rats, not observed in SAL rats. Intra-ventral hippocampal (vHPC) 
infusion of POM was sufficient to reduce dopaminergic activity in MAM rats. POM also increased 
novel object recognition in MAM rats and blocked stress-induced increases in dopaminergic 
activity in normal rats. To examine developmental effects of POM on MAM, MAM and SAL rats 
were treated peripubertally and DA neuron activity and vHPC pyramidal neuron activity were 
recorded in early or late adulthood. POM-treated MAM rats demonstrated normalized DA neuron 
activity and vHPC pyramidal neuron activity at both timepoints. Thus, POM indirectly regulates 
DA neuron activity by reducing increased vHPC activity and can prevent DA system hyperactivity 
in adult MAM rats following peripubertal administration. 
vi 
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since, however unsuccessful former attempts may have proved, there is still room to hope, 
that the industry, good fortune, or improved sagacity of succeeding generations  
may reach discoveries unknown to former ages.” 
-David Hume, An Enquiry Concerning Human Understanding, 1748
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1.0 GENERAL INTRODUCTION 
Portions of Chapter 1 are adapted from: 
Sonnenschein, S. F., & Grace, A. A. (2019). Insights on current and novel antipsychotic 
mechanisms from the MAM model of schizophrenia. Neuropharmacology. doi: 
10.1016/j.neuropharm.2019.05.009. 
1.1 PATHOPHYSIOLOGY OF SCHIZOPHRENIA 
1.1.1 Schizophrenia Within a Systems Neuroscience Perspective of Psychiatric Disorders 
Neurons do not generate cognition and behavior in isolation, but through dynamic 
connections between populations of cells that form complex networks across the nervous system. 
The formation, elimination, and modulation of these connections can result in long-term changes 
in function across development and in adaptation to external stimuli. When components of neural 
communication are dysfunctional, whether from genetic predisposition, environmental insults, or 
a combination of the two, the resulting maladaptive patterns of behavior may progress to what is 
referred to as psychiatric disorders (DeFelipe, 2006; Morrison and Murray, 2018).  
The schizophrenia spectrum of psychiatric disorders is most characteristically defined by 
psychotic symptoms, which include hallucinations and delusions. Diagnosis is based on a 
constellation of factors that also include negative symptoms (such as flattened affect and avolition) 
and cognitive impairment (Tandon et al., 2013). The psychotic features of schizophrenia typically 
emerge in late adolescence and early adulthood, indicative of neurodevelopmental influence 
(Fatemi and Folsom, 2009). The onset of psychosis may be abrupt or insidious, though the majority 
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of patients undergo a prodromal stage involving the development of sub-threshold symptoms, 
including attenuated psychotic symptoms, and deterioration in social and cognitive functioning 
(Larson et al., 2010). Patients diagnosed with schizophrenia face profound functional 
consequences. A minority of patients experience sustained symptom remittance with treatment and 
fully recover functional capability following the first episode of psychosis (FEP), but the majority 
of patients remain chronically ill with exacerbations and remissions of symptoms over time 
(Hegarty et al., 1994; Harrow et al., 2014; Zipursky et al., 2014). 
Patients may demonstrate markedly different symptom profiles and treatment response. 
Due to issues including heterogeneity and overlap with other disorders, schizophrenia fits the 
concept of a clinical syndrome better than a unified disease entity (Carpenter Jr, 2007). Though 
treatments exist, they are not precise and often leave a high disease burden, particularly in the 
absence of contextual factors, such as a supportive environment and access to resources (Eack and 
Newhill, 2007; Kennedy et al., 2014). In an effort to accelerate progress in psychiatric research, 
the National Institute of Mental Health developed the Research Domain Criteria (RDoC). The 
RDoC initiative aims to produce a more neurobiologically-based framework for psychiatric 
disorders, compared to their discrete categorization in the Diagnostic and Statistical Manual of 
Mental Disorders (DSM). RDoC-based research focuses on more “fundamental components” that 
are thought to be relevant across disorders (e.g. anxiety, social behavior, habit formation) and that 
can be linked to biological and behavioral measures. Similarly, the development of new treatments 
within the RDoC framework focuses on the identification of homogeneous subgroups of patients 
who exhibit a particular symptom rather than a disease-targeted panacea (Insel et al., 2010). This 
dissertation will focus on the dopamine (DA) system in relationship to the development and 
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treatment of psychotic symptoms, in the context of schizophrenia, but with potential relevance to 
related psychotic disorders. 
1.1.2 Dopamine Dysfunction in Schizophrenia 
The DA hypothesis of schizophrenia postulates that hyperactivity of the DA system drives 
psychotic symptoms (Van Rossum, 1967). Patients with schizophrenia consistently demonstrate 
measures of increased presynaptic DA function compared to healthy controls (Howes et al., 2012). 
There is also evidence for elevated DA activity in psychotic bipolar disorder (Jauhar et al., 2017), 
suggesting that DA neuron dysfunction may be a final common pathway of transdiagnostic 
psychotic symptoms.  
Pivotal studies that have provided support for the DA hypothesis have used positron 
emission tomography (PET) and single photon emission computed tomography (SPECT) imaging 
to examine radioligand displacement from DA receptors as a measure of DA activity. Patients with 
schizophrenia show increased DA release in response to amphetamine, compared to healthy 
controls (Laruelle et al., 1996; Abi-Dargham et al., 1998; Laruelle et al., 1999), which correlates 
with transient worsening of psychotic symptoms (Laruelle et al., 1999). Patients also demonstrate 
increased baseline synaptic DA in the striatum, measured in a DA depletion paradigm (Abi-
Dargham et al., 2000), which has been shown to correlate with their amphetamine-induced DA 
release (Abi-Dargham et al., 2009). Both measures are observed in antipsychotic drug (APD)-
naive patients and drug-free patients with prior APD treatment, and both predict treatment 
response of psychosis to APDs (Abi-Dargham et al., 2000; Abi-Dargham et al., 2009; Demjaha et 
al., 2012). Elevated striatal DA synthesis capacity, measured by fluorodopa uptake into DA 
terminals, is also consistently observed in patients and shown to correlate with psychotic severity 
(Howes et al., 2012). Numerous studies have found increased response capacity of the DA system 
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in individuals at clinical high risk (CHR) for psychosis, which correlates with greater severity of 
prodromal symptoms (Howes et al., 2009; Howes et al., 2011a; Howes et al., 2011b; Egerton et 
al., 2013). Longitudinal studies have further shown that there is a progressive increase in striatal 
DA function as CHR patients transition to full syndrome expression (Howes et al., 2011a). It has 
also been shown to predict conversion to psychosis in most (Howes et al., 2009; Egerton et al., 
2013), though not all (Howes et al., 2019) studies. The discrepancy may relate to factors including 
follow-up time and the influence of diagnostic criteria on determining transition rates, which can 
come down to small differences in severity and duration of symptoms (Howes et al., 2019). 
Elevated DA synthesis capacity is a less consistent finding in chronic patients in remission, shown 
to be significantly elevated compared to healthy controls in some studies (Reith et al., 1994; 
Meyer-Lindenberg et al., 2002; McGowan et al., 2004; Howes et al., 2013), though not all (Dao-
Castellana et al., 1997; Elkashef et al., 2000; Shotbolt et al., 2011), suggesting that increased DA 
function most clearly signals active psychosis.  
The observed elevation in DA is limited to subcortical (mesolimbic) projections of DA 
neurons to the striatum. PET studies have demonstrated that the rostral caudate (associative 
striatum) has the highest elevation of DA release and strongest correlation to psychotic symptoms 
in patients with schizophrenia (Kegeles et al., 2010; McCutcheon et al., 2017). In contrast, 
mesocortical projections display decreased DA release compared to healthy controls, which may 
contribute to impaired prefrontal-dependent cognitive processes. It is currently unknown what 
accounts for these coexisting differences in DA regulation, which have yet to be demonstrated in 
an animal model. Taken together, these findings provide strong support for the hypothesis that 
presynaptic DA dysfunction in subcortical projections, particularly to the associative striatum, is 
closely linked to the onset and expression of psychotic symptoms.  
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1.1.3 Hippocampal Dysfunction in Schizophrenia 
Elevated DA system activity in schizophrenia results from dysfunction in a larger 
hippocampal-midbrain-striatal circuit, with a primary locus of pathophysiology that appears to 
develop in the hippocampus (HPC). Deficits in the structure and function of the HPC are 
consistently observed in imaging and post-mortem studies of schizophrenia patients (Tamminga 
et al., 2010). Patients exhibit reduced functional recruitment of the HPC during declarative 
memory tasks (Heckers et al., 1998; Weiss et al., 2003). Patients also demonstrate increased HPC 
activity at rest and during cognitive tasks involving processing of salient information, as measured 
by cerebral blood flow (CBF) (Medoff et al., 2001) and blood oxygen level dependent (BOLD) 
signal in functional magnetic resonance imaging (fMRI) (Holt et al., 2006; Tregellas et al., 2014). 
Most studies report increased HPC glutamate levels in both first-episode and chronic patients, 
independent of medication status (Poels et al., 2014b), and changes in HPC metabolism and blood 
flow are associated with more severe psychotic symptoms in patients and  (Friston et al., 1992; 
Liddle et al., 1992; Gur et al., 1995) and those at CHR (Allen et al., 2015; Allen et al., 2017). 
Increased cerebral blood volume (CBV) has specifically been reported in the CA1 and subiculum 
of the HPC in patients with schizophrenia (Talati et al., 2014). Increased CBV is also present 
during the prodromal stage and predicts conversion to psychosis (Harrison, 2004; Schobel et al., 
2009) and HPC atrophy (Schobel et al., 2013). Cross-sectional comparison of CHR subjects to 
healthy controls generally does not reveal differences in HPC volume between the two populations 
(Velakoulis et al., 2006; Wood et al., 2008). However, longitudinal studies have demonstrated that 
CHR patients that convert to psychosis show a greater progression of grey matter reduction of the 
anterior CA1 and subiculum compared to those who do not convert to psychosis (Pantelis et al., 
2003; Borgwardt et al., 2007; Schobel et al., 2013). Reduced volume of the anterior HPC has also 
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been associated with illness duration (Velakoulis et al., 2006), although not all studies have found 
significant reduction over time (Lieberman et al., 2001) and chronic APD treatment or other 
external factors may contribute to progressive volume loss (Ho et al., 2011; Zipursky et al., 2012).  
Multiple lines of evidence have suggested that the increased HPC glutamate levels 
observed in schizophrenia is due to reduced parvalbumin (PV)+ GABA interneuron regulation of 
pyramidal neuron activity (Benes, 2000; Benes and Berretta, 2001). Loss of PV+ interneurons may 
at least in part be due to the vulnerability of their surrounding perineurnal nets (PNNs). PNNs are 
extracellular matrix structures important for the onset and closure of critical periods for 
developmental plasticity (Hensch, 2005). Their formation can be disrupted by oxidative stress, 
such that the PV+ interneurons fail to provide normal inhibitory input to the target pyramidal 
neurons. Antioxidant agents have been shown to protect PV+ interneurons from the damage caused 
by oxidative stress and normalize GABAergic inhibition (Cabungcal et al., 2013). Excitotoxicity 
from sustained oxidative stress and disinhibited pyramidal neuron activity (Schobel et al., 2009; 
Konradi et al., 2011; Schobel et al., 2013; Heckers and Konradi, 2015), may explain the correlation 
between increased regional glutamate levels and corresponding reduction in volume found in 
neuroimaging studies (Benes, 2000; Kraguljac et al., 2013; Do et al., 2015). 
1.1.4 The Development of DA Dysfunction via Hippocampal Dysfunction: Insights from 
Animal Models 
The observed dysfunction of the HPC and mesolimbic DA system in patients with 
schizophrenia can be unified in a pathophysiological model in which altered neurodevelopment 
via genetic risk combined with environmental stress leads to the disruption of the 
excitatory/inhibitory balance in regions including the HPC that, in turn, leads to psychotic 
symptoms via increased DA neurotransmission to the striatum. Many of the details of this theory 
7 
have been derived from experiments in animal models of schizophrenia. An inherent challenge in 
the use of rodent models for schizophrenia research is the inability to reproduce all dimensions of 
a uniquely human condition. Current models are thus limited to a subset of phenotypes, with no 
effective means to directly measure subjective mental states (Arguello and Gogos, 2006; Powell 
and Miyakawa, 2006). Despite their limitations, animal models are necessary tools for generating 
predictions and confirming causal relationships about the development, pathophysiology, and 
treatment of psychiatric disorders.  
Neurodevelopmental animal models are based on the hypothesis that deviations from 
normal maturation can produce long-term changes in the brain. The structural and functional 
abnormalities that result from early-life insults often only fully emerge in adulthood. This makes 
developmental models valuable for identifying processes through which a triggering event can 
progress into a pathological state and evaluating preventative interventions with potential use in 
the prodromal stage (Meyer and Feldon, 2010).  
Developmental consequences are commonly observed from environmental manipulations 
that involve early-life stress, such as social isolation or maternal separation (Harlow et al., 1965; 
Meaney et al., 1996). Adversity during the juvenile and adolescent period can shape the maturation 
of circuits that underlie emotional function (Cohen et al., 2013) and the resulting hyperresponsivity 
to stress is a core component of many psychiatric disorders (Heim and Nemeroff, 2001; Lupien et 
al., 2009). A large body of work highlights the importance of stress as a risk factor in the 
development of schizophrenia (Corcoran et al., 2003; van Os et al., 2010; Holtzman et al., 2013; 
Gomes and Grace, 2017). The correlation between early life stress and severity of positive 
symptoms (Ruby et al., 2017) may partially be due to the interaction between stress, the HPC, and 
the DA system (Belujon and Grace, 2015; Howes et al., 2017). Both CHR individuals and 
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schizophrenia patients demonstrate elevated DA release in response to stress compared to healthy 
controls (Pruessner et al., 2004; Mizrahi et al., 2012). Furthermore, peripubertal stress exposure in 
rats has been shown to increase DA neuron activity in adulthood, suggesting that stress before or 
during puberty is particularly impactful to the responsivity of the DA system (Gomes and Grace, 
2016).  
The HPC also shows marked vulnerability to stress across many psychiatric conditions.  It 
contains high expression of glucocorticoid receptors to respond to activation of the hypothalamic-
adrenal-pituitary (HPA) axis. While an elevation in glucocorticoids is essential to respond to 
perceived threat, chronic elevation can result in impaired function and atrophy (Sapolsky et al., 
1985; Sapolsky et al., 1990). Heightened stress responsivity, such as from insufficient prefrontal 
inhibition of activity in the amygdala (Rosenkranz and Grace, 2001, 2002; Gomes et al., 2019b), 
may contribute to HPC dysfunction and the emergent hyperdopaminergic state. It has thus been 
hypothesized that HPC dysfunction may contribute to the diathesis in prodromal patients that puts 
them at risk for developing psychosis in response to stress (Corcoran et al., 2003). 
The neonatal ventral hippocampal lesion (NVHL) model was the first to test the hypothesis 
that altered development of the ventral hippocampus (vHPC), the rodent analog of the anterior 
HPC in humans (Heilbronner et al., 2016), plays a critical role in the pathophysiology of 
schizophrenia. The model showed that a vHPC lesion in the early postnatal period results in the 
adult onset of behavioral abnormalities and DA dysfunction relevant to schizophrenia (Lipska et 
al., 1992; Lipska and Weinberger, 2000). Inspired by findings from the NVHL model and studies 
demonstrating the importance of immune activation during pregnancy as a risk factor for 
schizophrenia (Zuckerman et al., 2003; Canetta and Brown, 2012), another prominent 
neurodevelopmental model of schizophrenia was developed, the methylazoxymethanol acetate 
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(MAM) model (Johnston et al., 1981; Moore et al., 2006). The MAM model involves 
administration of the mitotoxin MAM to pregnant dams on gestational day 17, which correlates 
with the vulnerable timepoint of the 2nd trimester in humans to adverse events such as maternal 
infection (Brown, 2006). The offspring of MAM-treated dams (“MAM rats”) develop region-
specific disruption of neuronal maturation that results in adult phenotypes relevant to 
schizophrenia, in contrast to the offspring of dams that receive a saline injection, (“SAL rats”) 
(Flagstad et al., 2004; Moore et al., 2006; Modinos et al., 2015). Despite their different approaches, 
both the NVHL model and the MAM model display enhanced responsivity to stress (Lipska et al., 
1993; Zimmerman et al., 2013) in addition to similar structural and functional abnormalities in 
adulthood.  
One of the characteristic phenotypes observed in MAM rats is a hyperdopaminergic 
system. MAM rats demonstrate an increased number of spontaneously active DA neurons in the 
VTA, referred to as population activity, consistent with the hyperactive presynaptic DA function 
observed in schizophrenia (Lodge and Grace, 2007). Spontaneously active DA neurons fire in an 
irregular pattern in their basal state. When exposed to a behaviorally salient signal, DA neurons 
respond by firing bursts of action potentials, resulting in phasic DA release. Only spontaneously 
active DA neurons can produce burst firing in response to glutamatergic afferents (Grace and 
Bunney, 1984; Legault and Wise, 1999; Floresco et al., 2003; Lodge and Grace, 2006b). 
Regulatory inputs to the VTA normally modulate DA neuron population activity to vary the phasic 
signal based on environmental context, such as situations that are threatening or rewarding 
(Floresco et al., 2003).  
The MAM model has provided critical insights into how increased HPC drive leads to 
increased DA neuron activity. Silent DA neurons are held in a hyperpolarized state by the ventral 
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pallidum, which is controlled by a circuit originating with the vHPC. The subiculum of the HPC 
extends glutamatergic projections to the nucleus accumbens (NAc), which in turn inhibits the 
ventral pallidum. (Floresco et al., 2001; Lodge and Grace, 2006b). Similar to findings in 
schizophrenia patients (Benes and Berretta, 2001), MAM rats show loss of parvalbumin (PV+) 
interneurons in the vHPC (Lodge et al., 2009), resulting in a baseline hyperactive state from loss 
of inhibitory control of pyramidal cell activity (Lodge and Grace, 2007). Inhibition of GABAergic 
neurons in the ventral pallidum releases their inhibitory hold on DA neurons in the VTA (Floresco 
et al., 2003). This increases the population of spontaneously active DA neurons available for 
NMDA-mediated phasic burst firing in response to glutamatergic input from the pedunculopontine 
tegmentum (Floresco et al., 2001), which itself is enabled by the laterodorsal tegmentum (Lodge 
and Grace, 2006a). Activation of the vHPC in normal rats dramatically increases DA neuron 
population activity in the VTA, which is correlated with increased DA efflux in the associative 
areas of the ventral striatum and NAc, whereas inactivation of vHPC in MAM rats can normalize 
the DA neuron activity and related aberrant behavior (Floresco et al., 2003; Lodge and Grace, 
2007). 
1.1.5 Dopamine Dysfunction within an Aberrant Salience Framework 
The pathologically increased DA neuron population activity observed in MAM rats has 
been proposed to cause stimuli to produce a maximal DA response independent of context (Fig. 
1-1 A-B; Lodge and Grace, 2011), consistent with the “aberrant salience” framework of psychosis
(Kapur, 2003; Lisman et al., 2008). It has long been thought that that one of the functional roles 
of DA is to weight stimuli as attractive or aversive (Berridge and Robinson, 1998). Though 
traditionally studied for its role in reward prediction error, DA neurons also respond to novel or 
aversive stimuli in the absence of reward (Matsumoto and Hikosaka, 2009). Thus, it may be more 
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accurate to say that DA attributes salience to relevant stimuli (Kapur, 2003). It also has been 
suggested that DA projections in more ventral striatal regions produce a more value-related signal, 
whereas DA transmission in more dorsal striatal regions may carry a more salience-related signal 
(Lerner et al., 2015; Menegas et al., 2017) 
Presentation of novel stimuli (Strange and Dolan, 2001; Fyhn et al., 2002; Jenkins et al., 
2004) or exposure to stress (Linden et al., 2004; Valenti et al., 2011a) also produce a robust 
increase in HPC activity. Cortical areas send projections signaling sensory information to the 
entorhinal cortex, which acts as a gateway to the HPC via two inputs: the direct pathway (to the 
CA1) and the indirect pathway via the perforant path (dentate gyrus - CA3 - CA1) (Witter et al., 
2000; Lisman and Grace, 2005a). It has been hypothesized that recurrent projections from the 
dentate gyrus to and from the CA3 are involved in memory recall to predict what is likely to happen 
next, based on stored memory sequences, which is then sent to the CA1 via Schaffer collaterals. 
The CA1 is thought to compare the predictions that arrive from CA3 (previously experienced 
sensory information) with direct pathway input (new sensory information) to determine novelty, 
that may then go on to influence, and be further weighted by, DA activity to drive behavior 
(Lisman, 1999; Lisman and Grace, 2005b). 
When dysregulated, the abnormally heightened response to neutral stimuli may form the 
basis of delusions and hallucinations (Kapur, 2003). Furthermore, it has been suggested that 
dysregulated DA release in schizophrenia includes a reduction in adaptive phasic DA release in 
response to relevant stimuli (Maia and Frank, 2017). The reduction of relevant signal-to-noise may 
relate to reductions in functional connectivity of the striatum to cortical brain regions observed in 
fMRI studies (Fornito et al., 2013; Sarpal et al., 2015; Sarpal et al., 2017; Manivannan et al., 2019) 
and result in a general disintegration of sensory processing (McCutcheon et al., 
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2019a). Alternatively, it has been suggested that hallucinations may represent an extreme form of 
perceptual bias that incorporate prior beliefs. Dysregulated DA may weight the perception with 
the bias towards a (false-positive) signal being present (Horga and Abi-Dargham, 2019).   
There are current efforts toward trying to integrate current understandings of DA-based 
salience detection with the “salience network” (comprised of the insula and anterior cingulate), 
observed in resting state fMRI studies in humans (Seeley et al., 2007; Miyata, 2019). There is early 
evidence that DA synthesis capacity is related to salience network connectivity, suggesting a 
relationship between the different domains of salience processing that have been observed in 
human and rodent research (McCutcheon et al., 2019b). Future work may provide greater insight 
into how salience is processed across brain networks, its relationship to psychosis, and how best 
to treat abnormal salience processing. 
It has been proposed that APDs create detachment from symptoms by dampening the 
salience generated from increased striatal DA release, but they do not necessarily remove the 
mental schemas that attempt to make sense of the unusual experiences (Kapur, 2003; Kapur et al., 
2005a). The underlying cognitive processes likely involve complex connections between 
numerous brain regions that remain dysfunctional. Even within the DA system, current APDs 
reduce DA neuron hyperactivity, but they do not target or resolve the upstream HPC dysfunction.  
1.2 TREATMENTS FOR PSYCHOSIS IN SCHIZOPHRENIA 
1.2.1 Current Treatments for Schizophrenia 
The success of the first APD chlorpromazine in the 1950s was a breakthrough in the current 
era of pharmacotherapy and represented a shift in the conceptualization of psychiatric symptoms 
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as biological constructs that can be targeted and treated (López-Muñoz et al., 2005). In the decade 
following their established efficacy, it was suggested that APDs may work by acting on DA 
receptors (Carlsson and Lindqvist, 1963; Van Rossum, 1967). This was later confirmed by the 
finding that all APDs block D2 receptors, which is strongly linked to their antipsychotic effect 
(Seeman and Lee, 1975; Creese et al., 1976). Action at D2 receptors has since been proposed to be 
both necessary and sufficient for the therapeutic effect of current APDs on positive symptoms 
(Kapur and Remington, 2001). 
Much of the research on APDs has focused on their mechanisms of action to understand 
how they achieve their therapeutic effect. APDs are traditionally categorized as either first-
generation antipsychotics (FGAs), such as haloperidol, or second-generation antipsychotics 
(SGAs), such as clozapine, which act on a larger spectrum of receptor types, including 
serotonergic, cholinergic, and adrenergic receptors (Miyamoto et al., 2005). Due to the high level 
of heterogeneity within these broad designations, some argue that the current nomenclature is 
uninformative and should be replaced with a neuropharmacological-based naming system (Zohar 
et al., 2015). Like many psychoactive drugs, APDs have numerous physiological effects due to 
their rich pharmacology, although the antipsychotic effect of both FGAs and SGAs remains 
dependent on the D2 receptor and are given at doses that match D2 occupancy (Kapur and 
Remington, 2001).  
Most current APDs act as D2 receptor antagonists (Seeman, 1987), but to understand how 
FGAs and SGAs regulate the DA system, it is necessary to look beyond the receptor at downstream 
consequences on DA neuron activity. D2 antagonists block both postsynaptic and presynaptic D2 
receptors (autoreceptors). Acute administration of D2 antagonists in anesthetized rats increases DA 
neuron firing rate and bursting activity, primarily through blockade of somatodendritic D2 
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autoreceptors that normally provide negative feedback for the neuron (Grace and Bunney, 1986; 
Pucak and Grace, 1994). However, with repeated treatment there is a substantially depolarized 
membrane potential that culminates in inactivation such that the DA neuron is no longer able to 
generate action potentials. Inactivation can be reversed by compounds that inhibit DA neurons, 
such as DA agonists, whereas excitatory compounds are no longer capable of stimulating activity 
(White and Wang, 1983; Grace and Bunney, 1986). This phenomenon, referred to as 
depolarization block, is proposed to underlie the regulatory action of D2 antagonists on DA neuron 
hyperactivity (Grace et al., 1997; Arnt and Skarsfeldt, 1998). 
FGAs and SGAs have similar efficacy on positive symptoms and they are primarily 
distinguished in clinical use by differing side effect profiles (Leucht et al., 2013). One hypothesis 
is that differences in specificity of depolarization block between FGAs and SGAs may explain 
their comparable efficacy and difference in propensity to cause extrapyramidal side effects (EPS; 
Correll and Schenk, 2008). Acute administration of FGAs activates DA neurons in both the VTA 
and substantia nigra, whereas SGAs only activate DA neurons in the VTA (Bunney and Grace, 
1978; Chiodo and Bunney, 1985; Goldstein et al., 1993; Stockton and Rasmussen, 1996). 
Accordingly, FGAs produce depolarization block in both the VTA and SNc, whereas SGAs 
selectively produce depolarization block in the VTA (Fig. 1-2 A-B; Chiodo and Bunney, 1983; 
White and Wang, 1983; Grace and Bunney, 1986; Lane and Blaha, 1987; Goldstein et al., 1993). 
Dorsal regions of the striatum that receive DA projections from the SNc in humans are implicated 
in psychosis (Kegeles et al., 2010; Egerton et al., 2013), though this may relate to depolarization 
block of lateral regions of the VTA in rodents (related to the dorsomedial substantia nigra in 
humans). It has been suggested that differing pharmacokinetics may also contribute to their side 
effect profiles: SGAs typically dissociate from the D2 receptor more readily than FGAs, which 
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may make them more accommodating to physiological DA transmission (Kapur and Seeman, 
2001). In support of this hypothesis, quetiapine and clozapine, the SGAs with the fastest 
dissociation rates, show no greater risk of EPS than placebo across their dosage range, whereas 
risperidone and olanzapine, SGAs with slower dissociation rates from the D2 receptor, are more 
likely to cause EPS at high doses (Kapur and Seeman, 2001). 
The onset of depolarization block may relate to the range of latencies in clinical 
improvement of psychosis, which can occur as fast as 24 hours following the initial dose of an 
APD, with full effect after several weeks of treatment (Agid et al., 2003; Kapur et al., 2005b; 
Leucht et al., 2005). In normal rats, 21 days of repeated administration of FGAs and SGAs is 
necessary to reduce the number of spontaneously active DA neurons (Chiodo and Bunney, 1983; 
Grace and Bunney, 1986), whereas MAM rats undergo rapid onset of depolarization block 
following acute administration (Valenti et al., 2011b). Enhanced DA system excitability in MAM 
rats likely underlies the rapid onset of depolarization block, though it is unclear what enables this 
rapid response. 
D2 partial agonists, such as aripiprazole (ARI), activate the receptor to a lower degree than 
endogenous DA and are sometimes referred to as third generation APDs (Fig 1-2 C). They are 
thought to stabilize DA neurotransmission by reducing excessive striatal D2 stimulation and 
restoring deficient D2 stimulation in regions including the prefrontal cortex (PFC; Grace, 1991; 
Burris et al., 2002). In contrast to D2 antagonists, which are associated with a therapeutic effect at 
striatal D2 receptor occupancy of 65-70% and increased risk of EPS at D2 receptor occupancy 
exceeding 80% (Farde et al., 1992; Kapur et al., 2000), ARI has a therapeutic effect with 85-95% 
striatal D2 receptor occupation, yet does not produce EPS (Yokoi et al., 2002; Mamo et al., 2007). 
Furthermore, ARI has been shown to not produce D2 receptor upregulation or behavioral DA 
16 
supersensitivity in rats (Inoue et al., 1997; Tadokoro et al., 2011), and there is preliminary evidence 
that it may alleviate DA supersensitivity in humans (Tadokoro et al., 2017). D2 receptor partial 
agonists may thus be less likely to induce adverse effects related to DA supersensitivity, as 
observed following chronic D2 antagonist treatment (Silvestri et al., 2000; Chouinard et al., 2017). 
These differences between D2 receptor antagonists and D2 partial agonists may be related to their 
distinct methods of DA neuron regulation. 
1.2.2 Limitations of Current Antipsychotic Drugs 
APDs reduce psychotic symptoms in many patients (Leucht et al., 2009a). However, their 
therapeutic value is hindered by numerous side effects, limited efficacy across symptom domains, 
and failure to treat the primary cause of the disease, which can lead to a lifetime of maintenance 
treatment (Lieberman et al., 2005; Leucht et al., 2012).. These factors negatively impact quality of 
life and contribute to a high level of treatment nonadherence that typically results in relapse 
(Robinson et al., 2002; Lieberman et al., 2005). Current APDs are also unable to address 
heterogeneity, both between individuals with distinct pathologies (Demjaha et al., 2014; Howes 
and Kapur, 2014) and within an individual through different phases of the disease (Krystal and 
Anticevic, 2015). 
Approximately 30% of patients with schizophrenia display treatment resistance with little 
or no response to standard medication (Conley and Buchanan, 1997) and a higher rate, up to 60%, 
only partially respond to treatment (Kane, 1989). In the event of inadequate response, clinicians 
often resort to the combination of multiple APDs or augmentation with mood stabilizers and SSRIs 
(Stahl and Grady, 2004; Faries et al., 2005; Fleischhacker and Uchida, 2014). Despite its 
prevalence as a clinical strategy, there is limited evidence that long-term APD polypharmacy 
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benefits patients (Stahl and Grady, 2004), and may instead be detrimental due to increased 
frequency of adverse effects (Correll et al., 2007; De Hert et al., 2012).  
There are two overarching categories of treatment resistance. The first category includes 
patients who once responded to APDs but no longer do. This type of resistance often following 
relapse (Takeuchi et al., 2019) and may be related to DA supersensitivity following an 
upregulation in D2 receptors in response to chronic D2 antagonist administration (Emsley et al., 
2013). There are also patients who never responded to APDs whose psychotic symptoms have 
been proposed to not involve DA dysregulation (Howes and Kapur, 2014). Studies have shown 
that schizophrenia patients with low striatal DA synthesis capacity are more likely to be treatment 
non-responders (Demjaha et al., 2012; Demjaha et al., 2014). This subset of patients may still have 
a dysfunction involving the HPC-striatal-midbrain circuit, but given that a more active DA system 
responds faster to D2 blockade, the low responsivity of their DA system may not be a system 
conducive to depolarization block or other means of DA neuron downregulation (Grace and 
Gomes, 2018). However, these patients still show signs of glutamatergic dysfunction, including 
higher glutamate levels in the anterior cingulate compared to treatment responders (Demjaha et 
al., 2014; Mouchlianitis et al., 2015), suggesting that targeting the glutamate may alleviate 
symptoms for both treatment responders and non-responders.  
Current APDs exclusively target the DA system, necessitating further development of 
novel target options for treatment resistant patients. Among both treatment responders and 
nonresponders, there remain unmet needs in tolerability and safety of current APDs. In recent 
years, concern has been raised about the risk-to-benefit ratio of maintenance APD treatment, due 
to issues including DA supersensitivity and potential deleterious effects on brain structure and 
functioning (Murray et al., 2016; Chouinard et al., 2017). Treating patients with the minimum 
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necessary dose and using D2 partial agonists may minimize side effects and the risks associated 
with long term APD treatment, but targeting upstream brain regions may circumvent the issues 
associated with D2-targeting drugs and address additional symptoms.  
1.2.3 Novel Antipsychotic Mechanisms 
A key goal of APD research is the development of personalized medication, which requires 
reliable biomarkers to determine which treatment is most suitable for a patient's individual needs. 
A massive investment has gone into the development of novel target compounds with the hope 
that they will be more effective in treating a wider range of symptoms in schizophrenia.  
One of the most promising novel target candidates was group II metabotropic glutamate 
receptors (mGluRs), comprised of mGluR2 and mGluR3 (mGluR2/3). Unlike glutamate’s rapid 
excitatory action via ionotropic glutamate receptors, mGluRs modulate glutamate transmission, 
with the additional advantage of distinct expression patterns (Conn and Pin, 1997). The mGluR2/3s 
are prominently expressed in limbic brain regions, including the PFC, HPC, and amygdala 
(Nicoletti et al., 2011). They are primarily localized presynaptically as autoreceptors on 
glutamatergic terminals to negatively regulate glutamate release (Nicoletti et al., 2011).  
Following extensive preclinical support for mGluR2/3 as an APD target (Moghaddam and 
Adams, 1998; Cartmell et al., 1999, 2000; Lorrain et al., 2003; Greenslade and Mitchell, 2004; 
Homayoun et al., 2005; Pehrson and Moghaddam, 2010), an mGluR2/3 agonist from Eli Lilly, 
pomaglumetad methionil (POM), was advanced to clinical trials. It showed promise in preclinical 
research (Rorick-Kehn et al., 2007; Mezler et al., 2010). It demonstrated potential as a 
monotherapy in its first double-blind, randomized, placebo-controlled phase 2 clinical trial, and it 
was found to be well tolerated with no propensity to cause weight gain or EPS (Patil et al., 2007). 
This success was followed by a long line of disappointments in subsequent phase 2 trials as a 
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monotherapy or adjunct therapy (Adams et al., 2013; Stauffer et al., 2013; Downing et al., 2014) 
and failure to meet the primary endpoint as a monotherapy in a large phase 3 trial (Adams et al., 
2014; Marek, 2015).  
Later analyses of the clinical trials found that certain populations responded better to POM 
(Kinon et al., 2015), indicating that important questions remained about why those groups 
responded better and whether glutamatergic-targeting therapies may be best suited for certain 
populations. For example, early-in-disease patients responded better to POM treatment than 
chronic patients (Kinon et al., 2015), which could potentially be due to factors including treatment 
history and disease progression. Additionally, a study in mice showed that SGA administration 
can downregulate mGluR2 expression, thought to be due to action on 5-HT2A receptors, which 
may have contributed to the failure (Kurita et al., 2012). There were also efforts to develop 
mGluR2 positive allosteric modulators (PAMs) that would induce a leftward shift in the dose-
response curve for glutamate without directly acting at the glutamate site (Conn et al., 2009; Fraley, 
2009; Fell et al., 2012). They similarly showed promising results in APD screening assays 
(Lavreysen et al., 2013), though a compound tested by AstraZeneca once again did not show 
efficacy in patients with schizophrenia as a monotherapy (Litman et al., 2016). Despite the failure 
of the clinical trials, they are suggestive that there may be sub-populations of patients who may 
benefit most from novel drugs. 
1.2.4 Stage Specific Treatments 
The neurobiology of schizophrenia evolves over the course of the illness from the 
prodromal stage, where symptoms and cognitive impairment are present in attenuated form, to the 
first episode, with full symptom expression, to chronic illness, where symptoms persist at 
fluctuating levels. Longer duration of untreated psychosis (DUP) is associated with worse 
20 
treatment responses and outcomes (Perkins et al., 2005), suggesting that the timing of effective 
treatment in FEP is a critical factor in prognosis (Lieberman et al., 2019).  
No treatment has yet been conclusively proven effective for prevention of transition to 
psychosis. Prodromal interventions such as the use of SGAs (McGlashan et al., 2006), 
antidepressants (Cornblatt et al., 2007), and antioxidants, such as omega-3 fatty acids (Amminger 
and McGorry, 2012) have produced mixed success in reducing transition rates (McGorry et al., 
2008; Larson et al., 2010), though several meta-analyses have suggested that preventative 
treatments may increase time to transition and decrease the rate of conversion (Stafford et al., 
2013; van der Gaag et al., 2013).  
Consideration of the development of the circuits involved is necessary to enable effective 
stage-specific treatments. As previously described, there is growing evidence that HPC 
dysfunction is present at the prodromal stage. Stress, particularly in those who are predisposed to 
stress vulnerability, may strike at PV+ interneurons prior to the first episode. Protecting PV+ 
neurons as early as possible in the prodromal period may provide long lasting benefits in 
alleviating or preventing psychotic symptoms (Gomes et al., 2019b). Targeting 
excitatory/inhibitory dysfunction in the HPC is a possible intervention strategy in the early stages 
of psychosis, under the hypothesis that early intervention results in a better long-term outcome.  
1.3 PURPOSE OF STUDIES 
1.3.1 Rationale 
A similar progression of HPC dysfunction, including PV+ interneuron loss, increased 
glutamatergic drive and atrophy is observed in both patients with schizophrenia and the MAM 
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model (Moore et al., 2006; Heckers and Konradi, 2010; Modinos et al., 2015). The MAM model 
has been used to elucidate the role of the HPC in a circuit that leads to increased DA neuron 
population activity in the VTA (Lodge and Grace, 2007). Compounds that target the vHPC by 
either increasing function of PV+ interneurons or reducing the activity of pyramidal neurons may 
be used to normalize HPC output. Several studies have found success with using strategies to target 
vHPC dysfunction to normalize DA neuron activity and behavior in MAM rats (Gill et al., 2011; 
Gastambide et al., 2012; Perez and Lodge, 2013; Perez et al., 2013). Targeting upstream 
dysfunction has the potential to be more effective in treating schizophrenia in patients who have 
already developed the disease, but an ideal approach would involve intervention prior to the 
transition to psychosis, which may lead to a better long-term outcome (Perkins et al., 2005; Grace 
and Gomes, 2018). 
Studies in the MAM model have further demonstrated that the peripubertal period is a 
stress-sensitive window that can be targeted to prevent the development of MAM phenotypes in 
adulthood (Gomes and Grace, 2016). Previous work has shown that peripubertal administration of 
the benzodiazepine, diazepam, can prevent the increased anxiety-like behavior and basolateral 
amygdala hyperactivity, and normalize hyperdopaminergic activity normally present in adult 
MAM rats (Du and Grace, 2013, 2016a, b). Benzodiazepines are not a realistic prophylactic option 
clinically due to issues including dependence and tolerance (Longo and Johnson, 2000), but these 
studies demonstrate that decreasing stress or other means of reducing HPC activity during 
peripubertal period has the potential to circumvent the pathological processes that leads to DA 
system dysregulation (Grace and Gomes, 2018). They also highlight the potential for stage-specific 
pharmacotherapies involving optimal treatment strategies based on the neurobiological course of 
the disease (Krystal and Anticevic, 2015).  
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Glutamatergic regulation via mGluR2/3s is an unexplored option as an early intervention 
treatment for the long-term prevention of DA system hyperactivity. It has been reported that 
increased HPC activity, local reduction in PV + interneurons, and volume loss following repeated 
ketamine administration in adult mice can be prevented by coadministration with an mGluR2/3 
agonist (Schobel et al., 2013). The potential therapeutic effect of mGluR2/3 agonists has 
previously been suggested to be DA-independent due absence of mGluR2/3 expression in the VTA 
(Neki et al., 1996) and their lack of effect on DA levels at baseline (Pehrson and Moghaddam, 
2010). However, mGlu2/3 receptors are densely expressed in HPC, including the human anterior 
HPC (Blümcke et al., 1996) and corresponding vHPC (Neki et al., 1996). Furthermore, previous 
work has demonstrated APDs can produce different effects on DA neuron electrophysiology in 
MAM rats compared to SAL rats, such as rapid induction of depolarization block following D2 
antagonist administration (Valenti et al., 2011b). Therefore, it is possible that mGluR2/3 agonists 
may similarly demonstrate different effects between MAM and control rats. Exploration of DA 
system state-dependent differences of APD action may provide greater insight into preclinical 
testing of novel target mechanisms, such as mGluR2/3 agonists, and their potential for early 
intervention treatments.   
1.3.2 Hypothesis and Research Objectives 
In this dissertation, we hypothesize that both D2 partial agonists and mGluR2/3 agonists 
regulate the DA system in a state-dependent manner and peripubertal mGluR2/3 agonist 
administration can prevent emergence of vHPC abnormalities in MAM rats that lead to a 
hyperdopaminergic state in adulthood. In Chapter 2, we investigate whether ARI can modulate 
DA neuron activity in a state-dependent manner in MAM and SAL rats and whether its reduction 
of DA neuron activity is dependent on depolarization block. In Chapter 3, we determine the role 
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of mGluR2/3 receptors in the regulation of DA neuron activity. Finally, in Chapter 4 we examine 
whether peripubertal treatment with an mGluR2/3 agonist can prevent the DA system 
hyperactivity observed in adult MAM rats. Taken together, our findings suggest that clinically-
relevant models, such as the MAM model, can be used to determine how mGluR2/3 activation 
affects a system-wide disorder, and may more generally be used to observe the effects of APDs 
and potential preventative treatments for schizophrenia that may not be present in normal rodents 
or baseline conditions. 
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Figure 1-1: Hippocampal-striatal-dopamine dysregulation in schizophrenia 
(A) In a normal system, the hippocampus (HPC), regulates dopamine (DA) neuron population activity in the ventral
tegmental area (VTA), with variable gain based on context. The HPC sends glutamatergic input to the nucleus
accumbens in the ventral striatum, which sends inhibitory projections to the ventral pallidum. The ventral pallidum 
holds a proportion of DA neurons in an inhibited state. In response to relevant stimuli, only spontaneously active 
DA neurons can respond to glutamatergic input from the pedunculopontine tegmentum (PPTg), gated by the 
laterodorsal tegmentum (LDT), with burst firing. The DA signal to the striatum has topographic organization with 
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DA neurons in the substantia nigra pars compacta (SNc) projections to the dorsal striatum, lateral VTA projections 
to the associative striatum, and medial VTA projections to the ventral striatum. (B) In schizophrenia, the limbic 
HPC is in a pathologically hyperactive state and no longer responds appropriately to context. Increased excitatory 
input from HPC to the ventral striatum results in less inhibition of the ventral pallidum and fewer DA neurons held 
in a silent state. The increased DA signal is most prevalent in the associative striatum. 
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Figure 1-2: Antipsychotic drug modulation of DA neuron activity states 
(A) First generation D2 antagonist antipsychotic drugs (APDs) act on postsynaptic and presynaptic D2 receptors in
the striatum to produce depolarization block of DA neurons in the ventral tegmental area (VTA) and substantia nigra 
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pars compacta (SNc) and reduces DA neuron population activity in both regions. The DA signal is diminished to all 
domains of the striatum, resulting in both the antipsychotic effect and extrapyramidal side effects, including motor 
dysfunction. Following prolonged treatment, the system adapts by upregulating the number of D2 receptors, which 
can produce DA supersensitivity. (B) Second generation D2 antagonist APDs only produce depolarization block of 
DA neurons in the ventral tegmental area (VTA), resulting in a reduced DA signal to the associative and ventral 
striatum without effect on the DA neurons that project to the dorsal striatum. Thus, SGAs produce an antipsychotic 
effect without motor side effects. However, like first generation APDs, following prolonged treatment, there is an 
upregulation of D2 receptors, which can produce DA supersensitivity. (C) D2 partial agonists normalize DA neuron 
population activity by reducing hyperdopaminergic activity via DA neuron inhibition and increasing 
hypodopamineregic activity via postsynaptic stimulation. The downregulation of DA neuron activity does not occur 
through depolarization block and does not produce an upregulation of D2 receptors. 
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2.0 STATE-DEPENDENT EFFECTS OF D2 PARTIAL AGONIST ARIPIPRAZOLE ON 
DOPAMINE NEURON ACTIVITY IN THE MAM MODEL OF SCHIZOPHRENIA 
Chapter 2 is a modified version of: 
Sonnenschein, S. F., Gill, K. M., & Grace, A. A. (2019). State-dependent effects of the D 2 partial 
agonist aripiprazole on dopamine neuron activity in the MAM neurodevelopmental model of 
schizophrenia. Neuropsychopharmacology, 44(3), 572. 
2.1 INTRODUCTION 
The majority of current APDs are D2 receptor antagonists (Seeman and Lee, 1975; Kapur 
et al., 2000). A mechanism proposed for the therapeutic action of D2 receptor antagonists on DA 
dysregulation observed in schizophrenia (Laruelle and Abi-Dargham, 1999) is DA neuron 
depolarization block (Grace and Bunney, 1986; Grace et al., 1997). In depolarization block, 
following repeated treatment with D2 receptor antagonists, a substantially depolarized membrane 
potential results in over-excitation-induced cessation of spiking (Grace and Bunney, 1986) 
primarily due to blockade of somatodendritic D2 autoreceptors that provide local feedback 
inhibition of spike activity (Pucak and Grace, 1994, 1996). Depolarization block can be reversed 
by administration of a DA agonist, such as apomorphine. At low doses, apomorphine acts 
preferentially at D2 autoreceptors to sufficiently inhibit DA neurons in depolarization block to 
restore spiking activity, consistent with an APD-induced overexcitation rather than inhibition of 
DA neuron firing (Bunney and Grace, 1978; Grace and Bunney, 1986). The net result of 
depolarization block is a reduced number of spontaneously active DA neurons (Bunney and Grace, 
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1978; Braszko et al., 1981; Chiodo and Bunney, 1983; Grace and Bunney, 1986) available for 
phasic activation (Floresco et al., 2003) and striatal DA release (Lane and Blaha, 1987).  
Following prolonged D2 antagonist treatment, a compensatory upregulation of D2 receptors 
has been observed in humans and animal models that persists after APD discontinuation (O'Dell 
et al., 1990; See et al., 1990; Lidow and Goldman-Rakic, 1994; Silvestri et al., 2000; Tadokoro et 
al., 2011). The increase in D2 receptors is associated with increased behavioral sensitivity to DA. 
It has been proposed that DA supersensitivity underlies the relapse of psychotic symptoms 
following discontinuation of treatment or dose reduction, which may include the appearance of 
new or more severe psychotic symptoms. (Chouinard and Jones, 1980; Chouinard and Chouinard, 
2008). In animal models, increased striatal D2 receptor density is associated with an increased 
locomotor response to amphetamine and DA agonists following withdrawal from repeated APD 
administration (Montanaro et al., 1982; Samaha et al., 2007; Samaha et al., 2008; Gill et al., 2014). 
Although numerous studies have associated the emergence of DA supersensitivity to increased D2 
receptor density, the nature of the relationship is not clearly understood. There have been examples 
of increased D2 receptors during ongoing APD treatment without behavioral evidence of DA 
supersensitivity (Samaha et al., 2007; Samaha et al., 2008) and chronic APD treatment regimens 
that have not resulted in D2 receptor upregulation (Wilmot and Szczepanik, 1989), suggesting a 
complex relationship potentially based on factors including dose and treatment regimen.  
In contrast to the D2 receptor antagonism observed with other APDs, ARI is a D2 receptor 
partial agonist. ARI’s unique mechanism of action demonstrates properties of a functional agonist 
or antagonist in animal models of DA hypoactivity and hyperactivity, respectively, thus providing 
stabilization of the DA system (Grace, 1991; Burris et al., 2002). In contrast to both first-generation 
APDs and other second-generation APDs, there is evidence that ARI may not induce upregulation 
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of D2 receptors or DA supersensitivity (Inoue et al., 1997; Tadokoro et al., 2011). Due to its unique 
characteristics, including absence of DA supersensitivity following withdrawal from chronic 
treatment (Tadokoro et al., 2011), we hypothesized that ARI does not induce DA neuron 
depolarization block.  
Animal models provide a useful tool to study the state-dependent action of drugs that may 
not be readily observed in a normal system. To model the hyperdopamineregic state characteristic 
of schizophrenia we have utilized MAM rats, born with a developmental disruption induced 
through administration of this DNA alkylating agent to pregnant dams at gestational day 17 
(GD17). Adult offspring of MAM-treated rats demonstrate anatomical, behavioral, 
pharmacological, and physiological abnormalities consistent with phenotypes observed in patients 
with schizophrenia (Moore et al., 2006; Lodge and Grace, 2007; Lodge et al., 2009; Modinos et 
al., 2015) As a consequence of hippocampal hyperactivity, also observed in patients with 
schizophrenia (Kegeles et al., 2000; Schobel et al., 2009; Schobel et al., 2013), MAM rats display 
increased DA neuron population activity (Lodge and Grace, 2007) that rapidly results in 
depolarization block following acute administration of first and second generation APDs (Valenti 
et al., 2011b). MAM rats thus provide a clinically relevant model to study state-dependent effects 
of acute and repeated ARI administration on the DA system with the aim of clarifying the range 
of action of ARI at D2 receptors.  
2.2 METHODS 
Subjects 
All procedures were conducted in accordance with the Guide for the Care and Use of 
Laboratory Animals by the United States Public Health Service and approved by the University of 
31 
Pittsburgh Institutional Animal Care and Use Committee. Timed pregnant Sprague-Dawley dams 
(Envigo, Indianapolis, IN) were obtained on GD15 and MAM (20 mg/kg, i.p., Midwest Research 
Institute, Kansas City, MO) or saline (SAL; 1 ml/kg, i.p.) was administered on GD17. The male 
pups were weaned on postnatal day 23 and pair-housed with littermates in a temperature (22°C)- 
and humidity (47%)-controlled facility on a 12 h light/dark cycle (lights on 7 AM to 7 PM) with 
ad libitum food and water. Rats were used for experiments at 3-6 months of age (≥ 300 g). 
Antipsychotic Drug Administration 
MAM and SAL rats were assigned randomly to treatment groups of ARI (3 mg/kg or 10 
mg/kg; Sigma Aldrich, St Louis, MO), or vehicle (VEH). Treatments were administered orally 
using palatable vanilla wafers to which the rats were habituated for 2 d prior to treatment. Oral 
administration was used to circumvent injection stress and better approximate the clinical protocol 
(Ferguson and Boctor, 2009), as previously described (Du and Grace, 2013; Gill et al., 2014). ARI 
was placed on a wafer containing 0.2 ml liquid sugar and dissolved into the wafer with an 
additional 0.2 ml liquid sugar. VEH-treated rats were administered the same preparation without 
drug. Rats were placed individually into transport tubs to consume the wafers (usually <10 min) 
before being returned to home cages. 
For acute treatments, ARI or VEH wafers were consumed 2 h prior to the start 
of electrophysiological recording to observe effects at peak brain concentration as 
previously reported following oral administration in rats (Shimokawa et al., 2005). For repeated 
treatments, ARI and VEH wafers were administered at approximately 9 AM daily for 21d 
and rats were recorded either the following day or with 7d withdrawal. 
Acute Haloperidol Administration 
 MAM rats were injected with haloperidol (HAL; 0.6 mg/kg, i.p; Sigma Aldrich) dissolved
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 in 0.23% glacial acetic acid in distilled H2O and returned to their home cage. Recordings 
took place 1 h following HAL administration, which was shown to be sufficient time to 
induce depolarization block in MAM rats (Valenti et al., 2011b).  
Electrophysiological Recordings 
The activity state of DA neurons in the VTA was measured using in vivo extracellular 
recordings. Rats were anesthetized with chloral hydrate (400 mg/kg; i.p.) and placed on a 
stereotaxic frame (Kopf, Tujunga, CA). Supplemental anesthesia was administered i.p. to 
maintain suppression of the hind limb withdrawal reflex. Body temperature was maintained at 
37°C with a temperature-controlled heating pad (CWE Inc., Ardmore, PA). Single-barrel glass 
electrodes (WPI, Sarasota, FL) were pulled vertically (PE-2, Narasige, Japan), broken under a 
microscope to an impedance of 6-8 MΩ, and filled with 2 M NaCl containing 2% Chicago Sky 
Blue dye in 2 M saline. Electrodes were lowered through the VTA from 5.3-5.7 mm posterior, 
0.6-1.0 mm lateral, and 6.5-9.0 mm ventral from the top of brain via a hydraulic micropositioner 
(Kopf). Single-unit activity was obtained using an amplifier (Fintronics, Orange, CT) using a 
highpass filter at 30 Hz and lowpass at 16 kHz. DA neurons were classified based on established 
criteria, including a biphasic action potential with duration >2.2 ms, a slow firing rate (1-10 Hz), 
and irregular and burst firing patterns with the bursts characterized by an interspike interval of 
80-160ms (Grace and Bunney, 1983; Grace and Bunney, 1984; Ungless and Grace, 2012). 
Recordings were performed by making 6-9 vertical electrode passes (“tracks”) in a 
predetermined grid pattern with each track separated by 0.2 mm. The activity of each DA neuron 
was recorded for at least 1 minute of stable spontaneous activity with a signal-to-noise ratio 
greater than 2:1 using LabChart software (AD Instruments, Colorado Springs, CO). Three 
parameters were analyzed: (1) the average number of 
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spontaneously active DA neurons encountered per electrode track (“population activity”), (2) 
average firing rate and (3) the percentage of spikes that occurred in bursts (%SIB). 
In a subset of rats, after the first six tracks rats were administered apomporphine (100- 200 
μg/kg i.p. or 20 μg/kg i.v., in saline; Sigma-Aldrich) for acute and repeated ARI recordings or ARI 
(1 mg/kg in saline i.p.; Sigma-Aldrich) for acute HAL recordings. Apomorphine was administered 
in incrementally increasing doses until approximately a 50% decrease in baseline firing rate or 
bursting activity was detected in the DA neuron. Immediately following i.v. administration or 10 
min following i.p. administration, an additional six tracks were recorded. 
Histology 
Electrode placement was verified following each experiment via electrophoretic ejection 
of Chicago Sky Blue dye from the tip of the recording electrode (-20 μA constant current, 20 
min). Rats were then overdosed with chloral hydrate and decapitated. The brains were removed 
and fixed for at least 48 hours (8% paraformaldehyde in PBS), cryoprotected (25% sucrose in 
PBS) until saturated, and sliced on a cryostat into 60μm sections, which were mounted onto 
gelatin-coated slides. Slides were stained with a mixture of cresyl violet and neutral red for 
verification of electrode sites with reference to a stereotaxic atlas (Paxinos and Watson, 2007). 
Analysis 
Analysis of firing rate and bursting activity was performed using NeuroExplorer (Plexon, 
Dallas, TX). Population activity (“cells/track”) was averaged within each animal and then across 
animals in each group, whereas the firing rate and burst activity of each neuron was counted as an 
independent replicate and averaged across animals in a group. Significance for acute and repeated 
ARI experiments was assessed with a two-way ANOVA (MAM x Treatment) followed by Tukey 
post-hoc comparisons. Significance for depolarization block experiments was assessed with a two-
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tailed, paired t-test and the Wilcoxon signed-rank test was used for nonnormally distributed data. 
Significance for the haloperidol experiment was assessed with a oneway ANOVA followed by 
Tukey post-hoc and cells/track comparisons were made with a twotailed paired t-test. All statistics 
were calculated using SigmaPlot (Systat Software, San Jose, CA) and all data are represented as 
the mean ± SEM. 
2.3 RESULTS 
2.3.1 Acute Aripiprazole Administration Reduces VTA DA Neuron Activity of MAM but 
Not SAL Rats 
Electrophysiological recordings were conducted from MAM rats and SAL rats, with each 
group receiving either VEH or ARI (3 mg/kg or 10 mg/kg, p.o.). VEH-treated MAM rats (n = 6
rats, 63 neurons) exhibited the anticipated elevation in population activity with an average of 1.7 
± 0.1 cells/track compared to VEH-treated SAL rats (n = 8 rats, 61 neurons), which had an average 
of 1.1 ± 0.1 cells/track (Fig. 2-1 A; 2-way ANOVA main effects: for MAM, F(2,40) = 3.189,  p 
= 0.010; for ARI, F(2,40) = 5.049, p = 0.011; MAM-by-ARI interaction: F(2,40) = 5.882, p = 
0.005; post hoc MAM control vs SAL control: p = 0.001). Acute ARI treatment significantly 
reduced DA neuron population activity in MAM rats, both at 3 mg/kg (n = 6 rats, 37 neurons; 
post hoc MAM control vs MAM 3 mg/kg: p = 0.007) and 10 mg/kg (n = 10 rats, 63 neurons; 
post hoc MAM control vs MAM 10 mg/kg: p = 0.001) compared to VEH-treated MAM rats. In 
contrast, there was no reduction in DA neuron population activity in ARI-treated SAL rats, at 
3 mg/kg (n = 6, 41 neurons), or 10 mg/kg (n = 8 rats, 66 neurons), compared to VEH-treated 
SAL rats (Fig 2-1 A). There was no significant change in firing rate (Fig. 2-1 B) or bursting 
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(Fig. 2-1 C) with ARI treatment compared to VEH treatment in MAM or SAL rats. There was 
also no overt shift in the distribution of firing rate or bursting (Fig 2-1 D-E), despite the 
reduction in population activity observed in MAM rats. In ARI-treated MAM rats, at both 3 mg/
kg and 10 mg/kg, a systemic injection of apomorphine (100-200 μg/kg i.p) reduced firing rate 
and bursting activity of DA neurons held during injection. In an example neuron, apomorphine 
reduced firing rate of a DA neuron from 5.2 Hz to 3.1 Hz and the percentage of spikes in burst 
from 22.2% to 0% 5 min following the injection (Fig 2-1 F). An additional six tracks were 
recorded following apomorphine injection, without significant change in population activity 
compared to tracks recorded pre-apomorphine (Fig 2-1 G) and a leftward shift in the distribution 
of the firing rate and bursting activity of recorded DA neurons recorded post-apomorphine 
compared to preapomorphine (Fig 2-1 H-I). 
2.3.2 Repeated Aripiprazole Administration Reduces VTA DA Neuron Activity of MAM but 
Not SAL Rats 
To evaluate the effects of repeated ARI treatment, MAM and SAL rats received 21d of 
ARI (10 mg/kg) or VEH daily treatment p.o. and their VTA activity was recorded the following 
day. VEH-treated MAM rats (n = 6 rats, 66 neurons) displayed a significant elevation in DA neuron 
population activity (average 1.9 ± 0.1 cells/track) compared to VEH-treated SAL rats (Fig. 2-2 A; 
n = 6 rats, 38 neurons; average 1.0 ± 0.1 cells/track; 2-way ANOVA main effects: for MAM, 
F(1,21) = 16.401, p < 0.001; for ARI, F(1,21) = 11.602, p = 0.003; MAM-by-ARI interaction: 
F(1,21) = 9.223, p = 0.006; post hoc MAM control vs SAL control: p < 0.001). 
Repeated ARI treatment significantly reduced DA neuron population activity in ARI-
treated MAM rats (n = 7 rats, 45 cells) compared to VEH treated MAM rats to an average of 1.1 
± 0.1 cells/track (Fig 2-2 A; 2-way ANOVA; post hoc MAM ARI vs MAM control: p < 0.001). In 
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contrast, there was no reduction in DA neuron population activity in ARI-treated SAL rats (n = 6 
rats, 37 neurons; average 0.9 ± 0.1 cells per track), compared to VEH-treated SAL rats (Fig 2-2 
A). There was no significant change in firing rate with repeated ARI treatment compared to VEH 
treatment in MAM or SAL rats (Fig. 2-2 B; control baseline: 3.9 ± 0.3 Hz; control ARI: 4.1 ± 0.3 
Hz; MAM baseline: 4.0 ± 0.2 Hz; MAM ARI: 4.0 ± 0.3 Hz), and a main effect of ARI treatment 
on bursting activity in MAM and SAL rats (Fig. 2-2C; control baseline: 26.9 ± 4.2%; control ARI: 
37.9 ± 4.3%; MAM baseline: 33.4 ± 3.0%; MAM ARI: 41.4 ± 3.5%; 2-way ANOVA F(1,193) = 
6.016, p = 0.015). In MAM rats that received repeated ARI treatment, a systemic injection of 
apomorphine (200 μg/kg i.p) resulted in no significant change in DA neuron population activity in 
an additional six tracks that were recorded 10 min following the injection compared to tracks 
recorded preapomorphine (Fig 2-2 D); a leftward shift in the firing rate and bursting activity of 
DA neurons recorded post-apomorphine compared to pre-apomorphine was also observed (Fig 2-
2 E-F). 
2.3.3 Persistent Reduction of VTA DA Neuron Activity Following Withdrawal From 
Repeated Aripiprazole Administration 
Given our findings that acute and repeated ARI treatment results in a reduction in VTA 
DA neuron activity in MAM rats that is not restored by apomorphine administration, we examined 
whether this reduction remained following an extended 7d withdrawal from 21d repeated 
treatment. VEH-treated MAM rats (n = 5 rats, 66 neurons) displayed a significant elevation in DA 
neuron population activity with an average of 1.7 ± 0.1 cells/track, compared to VEH-treated SAL 
rats (n = 8 rats, 62 neurons), with an average of 1.0 ± 0.1 cells/track (Fig. 2-3 A; 2-way ANOVA 
main effects: for MAM, F(1,24) = 16.024, p < 0.001; for ARI, F(1,24) = 35.985, p < 0.001; MAM-
by-ARI interaction: F(1,24) = 25.671, p < 0.001; post hoc MAM control vs SAL control: p < 
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0.001). DA neuron population activity remained reduced in MAM rats following 7d withdrawal 
from 21d repeated ARI treatment (n = 6 rats, 37 neurons) compared to VEH-treated MAM rats 
with an average of 0.8 ± 0.1 cells/track and of spikes in bursts (Fig 2-3 A; 2-way ANOVA; post 
hoc MAM ARI vs MAM control: p < 0.001). In contrast, there was no reduction in DA neuron 
population activity in ARI-treated SAL rats (n = 9 rats, 61 neurons), with an average of 0.9 ± 0.1 
cells/track (Fig 2-3 A). MAM rats withdrawn from repeated ARI treatment displayed a significant 
reduction in firing rate (Fig. 2-3 B; control baseline: 3.7 ± 0.2 Hz; control ARI: 3.5 ± 0.2 Hz; MAM 
baseline: 3.7 ± 0.2 Hz; MAM ARI: 2.3 ± 0.3 Hz; 2-way ANOVA; main effects: for MAM, F(1,222) 
= 6.029, p = 0.015, for ARI, F(1,222) = 10.019, p = 0.002; MAM-by-ARI interaction: F(1,222) = 
6.268, p = 0.013; post hoc MAM ARI vs MAM control: p < 0.001) and there was a main effect of 
ARI treatment on bursting activity of VTA DA neurons in MAM and SAL rats withdrawn from 
repeated ARI treatment (Fig. 2-3 C; control baseline: 34.2 ± 3.4; control ARI; 27.6 ± 3.4% MAM 
baseline: 35.7 ± 3.3%; MAM ARI: 25.0 ± 4.3%; 2-way ANOVA; main effect for ARI, F(1,222) = 
5.772, p = 0.017), which was reflected in the distribution of DA neurons recording in ARI-treated 
MAM rats compared to VEH-treated MAM rats (Fig. 2-3 D-E). In MAM rats withdrawn from 
repeated ARI treatment, a systemic injection of apomorphine (200 μg/kg i.p or 20 μg/kg, i.v.) did 
not cause a significant change in DA neuron population activity in an additional six tracks that 
were recorded 10 min following the i.p. injection (n = 3 rats) or immediately following an i.v. 
injection (n = 1 rat) compared to tracks recorded pre-apomorphine (Fig 2-3 F). There was also a 
leftward shift in the firing rate and, more prominently, bursting activity of DA neurons recorded 
post-apomorphine compared to pre-apomorphine (Fig. 2-3 G-H). 
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2.3.4 Acute Aripiprazole Administration Reverses Haloperidol-Induced Depolarization 
Block in MAM Rats 
To determine the effect of acute ARI administration on depolarization block, six tracks 
were recorded in the VTA of MAM rats 1 h following acute treatment with haloperidol (0.6 mg/kg, 
i.p.) and an additional six tracks were recorded 10 min following acute ARI administration (1
mg/kg, i.p.). An example DA neuron recorded before ARI administration displayed an average 
firing rate of 2.5 Hz with 15.9% of spikes fired in bursts. The same neuron displayed a firing rate 
of 1.9 Hz with 3.9% of spikes fired in bursts following ARI administration (Fig 2-4 A). There was 
a significant increase in the number of spontaneously active DA neurons recorded after acute ARI 
administration (1.4 ± 0.1 cells/track) compared to before (0.6 ± 0.1 cells/track; paired t-test; t(7) = 
-4.031, p = 0.005). In contrast, there was no change in DA neuron population activity in tracks
recorded after VEH administration (1 ml/kg saline, i.p., 0.7 ± 0.2 cells/track) compared to before 
(0.8 ± 0.2 cells/track; Fig. 2-4 B-D). There was no significant difference in the firing rate (Fig. 2-
4 E) or bursting activity (Fig. 2-4 F) between groups.  
39 
Figure 2-1: Acute administration of ARI reduces DA neuron activity in the VTA in MAM but not SAL rats 
(A) 2 h following oral ARI administration, MAM rats displayed a reduced number of spontaneously active DA
neurons in the VTA compared to MAM rats that received VEH administration, which was not observed in SAL rats. 
There were no significant differences in the firing rate (B-C) or percentage of spikes in bursts (D-E) between ARI 
and VEH administration in MAM or SAL rats. (F) An example trace of a DA neuron recorded before and 5 min 
after APO, which was administered i.p. following six tracks, 10 min prior to recording an additional six tracks. APO 
reduced the firing rate and bursting activity of the DA neuron. (G) APO administration did not significantly reduce 
DA neuron population activity in the VTA of ARI-treated MAM rats, although there was a trend toward reduced 
spontaneous activity and a leftward shift in the distribution of firing rate (H) and % of spikes in bursts (I) in neurons 
recorded after APO compared to tracks recorded pre-APO. 
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Figure 2-2: Repeated administration of ARI for 21d p.o. reduced DA neuron activity in the VTA in MAM but 
not SAL rats 
(A)24h following 21d repeated ARI treatment, MAM rats displayed a reduced number of spontaneously active DA 
neurons in the VTA compared to MAM rats that received VEH administration, which was not observed in SAL rats. 
There was no significant difference in the firing rate (B) of DA neurons between ARI and VEH administration in 
MAM or SAL rats and there was a main effect of ARI treatment on the percentage of spikes in bursts (C). In MAM 
rats that received ARI, APO was administered i.p. following six tracks, 10 min prior to recording an additional six 
tracks. (D) APO administration did not significantly reduce DA neuron population activity in the VTA of ARI-
treated MAM rats and produced a leftward shift in the distribution of firing rate (E) and % of spikes in burst (F) in 
DA neurons recorded after APO compared to tracks recorded pre-APO. 
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Figure 2-3: Spontaneous DA neuron activity in the VTA of MAM rats remains reduced following 7d 
withdrawal from 21d ARI treatment in a manner distinct from depolarization block 
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(A)MAM rats displayed reduced VTA DA neuron following 7d withdrawal from 21d repeated ARI treatment
compared to VEH treatment, which was not observed in SAL rats. (B) MAM rats withdrawn from repeated ARI 
treatment displayed a reduced firing rate of DA neurons compared to VEH treated MAM rats, which was not 
observed in SAL rats. (C) ARI treatment reduced the percentage of spikes in bursts in both MAM and SAL rats, 
compared to VEH-treated rats. This was evident as a leftward shift in the distribution of both firing rate (D) and 
bursting activity (E) of DA neurons in ARI-treated MAM rats compared to VEH-treated MAM rats. In MAM rats 
that received ARI, APO was administered i.p. or i.v. following six tracks, prior to recording an additional six tracks. 
(F) APO administration did not significantly change DA neuron population activity in the VTA of ARI-treated
MAM rats and produced a leftward shift in the distribution of firing rate (G) and % of spikes in burst (H) in DA 
neurons recorded after APO compared to tracks recorded pre-APO. 
Figure 2-4: Reversal of haloperidol-induced depolarization block in MAM rats via acute ARI administration 
(A) 1 h following acute haloperidol (0.6 mg/kg, i.p.) administration in MAM rats, an example trace of a DA neuron
demonstrates a reduction in DA neuron firing rate and bursting activity 5 min following acute ARI (1 mg/kg, i.p.) 
compared to pre-ARI. (B-C) Within-subject changes in average DA neuron population activity in the six tracks 
recorded before ARI or saline administration in HAL-treated MAM rats compared to the six tracks recorded after 
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ARI or saline administration. (D) Acute ARI administration resulted in an increase in the average number of DA 
cells/track in HAL-treated MAM rats post-ARI administration compared to pre-ARI administration.  In contrast, 
there was no difference in population activity in tracks recorded post-saline administration. There was no significant 
change in the average firing rate (E) or bursting activity (F) in DA neurons recorded before and after ARI or VEH 
administration. 
2.4 DISCUSSION 
Unlike many other clinically available APDs, which exert their effects through D2 receptor 
antagonism, ARI is a D2 partial agonist thought to stabilize dopaminergic tone (Burris et al., 2002), 
although the mechanism underlying its state-dependent effect is unclear. The current study 
examined whether ARI reduces DA neuron activity in vivo in a normal and hyperdopaminergic 
system via overexcitation-induced depolarization block, as observed following D2 antagonist 
administration. We demonstrate that ARI is able to state-dependently decrease the number of 
spontaneously active DA neurons in the VTA in the MAM rodent model of schizophrenia in a 
manner distinct from D2 receptor antagonists. Furthermore, after depolarization block-driven 
decrease in DA neuron population activity (Grace and Bunney, 1986; Valenti et al., 2011b; Gill et 
al., 2014), ARI increased DA neuron population activity secondary to reversal of APD-induced 
depolarization block, as observed with low-dose administration of a DA agonist (Grace and 
Bunney, 1986; Valenti et al., 2011b). The interpretation of these results is limited to male rats and 
the chosen treatment and dose regiment. Female rats were excluded from the present study due to 
differences in DA neuron activity between female MAM and SAL rats across the estrous cycle 
(Perez et al., 2014). Examination of ARI’s action in female rodents across the estrous cycle is a 
necessary future direction, especially given reported differences in APD response between male 
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and female patients (Goldstein et al., 2002) and in female patients across the menstrual cycle 
(Bergemann et al., 2007). 
Aripiprazole Produces a Rapid and Long-Lasting Reduction of Hyperdopaminergic Activity Only 
in MAM Rats 
ARI, at both 3 mg/kg and 10 mg/kg, reduced DA neuron population activity in the VTA of 
MAM rats 2h following oral administration without affecting SAL rats, similar to the rapid 
reduction of population activity in MAM rats follow D2 receptor antagonist APD administration 
(Valenti et al., 2011b). The reduction was also present following 21d repeated ARI treatment and 
persisted 7d following withdrawal from repeated treatment, suggesting a persistent change in the 
DA system, as previously observed following withdrawal from repeated HAL treatment (Gill et 
al., 2014). However, unlike D2 receptor antagonists (Valenti et al., 2011b; Gill et al., 2014), ARI 
did not reduce DA neuron activity in SAL rats following repeated treatment or following 7d 
withdrawal from repeated treatment. Consistent with the lack of observed change in spontaneous 
DA neuron activity in control rats, an in vivo microdialysis study has previously shown that acute 
ARI administration does not affect cortical or striatal extracellular DA levels in rats following 
acute and repeated oral administration (Jordan et al., 2004). Repeated oral ARI administration has 
also been shown to block elevated GTPase activity stimulated by the DA agonist quinpirole, but 
ARI alone does not stimulate GTPase activity (Inoue et al., 1997). In contrast, (Li et al., 2004) 
demonstrated a reduction in extracellular DA levels in the PFC and NAc following acute ARI 
administration at 10 mg/kg, administered subcutaneously. These differences may be explained by 
differing administration methods, as even 21 d repeated administration of ARI 40 mg/kg p.o. has 
been shown to not significantly effect striatal DA levels (Jordan et al., 2004). Our results 
demonstrate that ARI is able to reverse the increased DA neuron activity, as observed in MAM 
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rats, without effect in a normal system, and that the reduction in DA neuron activity can remain 
stabilized following withdrawal from repeated treatment.  
Aripiprazole Does Not Reduce VTA Dopamine Neuron Activity via Depolarization Block 
In contrast to the reduction DA neuron population activity in MAM rats via depolarization 
block following acute treatment with D2 antagonists (Valenti et al., 2011b), the present data 
suggest that ARI administration does not induce depolarization block. The presence of 
depolarization block has been verified previously by administering low doses of the DA agonist 
apomorphine, which leads to an inhibition-driven reactivation of neurons previously in a 
hyperexcitation-induced block (Bunney and Grace, 1978; Grace and Bunney, 1986; Valenti et al., 
2011b). In contrast, low doses of apomorphine failed to increase population activity in MAM rats 
following acute or following 21d repeated ARI treatment. In addition, it did not affect population 
activity following 7d withdrawal from repeated ARI treatment. However, in all cases, 
administration of apomorphine produced a leftward shift in the distribution of firing rate and, more 
prominently, bursting activity of spontaneously active DA neurons recorded post-injection. In 
some cases, this resulted in a reduction in the number of spontaneously active DA neurons, notably 
observed following acute ARI administration, possibly because neurons with a previously low 
firing rate ceased firing. Therefore, the local feedback from the action of apomorphine presumably 
on D2 autoreceptors resulted in a net reduction in DA activity of ARI-treated MAM rats, rather 
than an increase in spontaneous activity which would be observed if the reduction in population 
activity was due to overexcitation-induced depolarization block. Although ARI displayed 
antagonist-like reduction of hyperdopaminergic activity in MAM rats, it did not appear to do so 
through antagonist action at presynaptic D2 receptors that would result in depolarization block. 
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The question remains of how ARI reduces DA neuron population activity in MAM rats. It 
has been hypothesized that ARI simultaneously acts as an antagonist at D2 receptors 
postsynaptically and an agonist presynaptically (Kikuchi et al., 1995; Oshiro et al., 1998; Burris et 
al., 2002) based on differences in receptor reserve (Burris et al., 2002). In the presence of a receptor 
reserve, ARI behaves like an agonist, and in its absence, ARI predominantly displays antagonist 
properties (Kikuchi et al., 1995). The greater number of presynaptic spare receptors may underlie 
ARI’s autoreceptor selectivity to inhibit neuron firing (Kikuchi et al., 1995; Burris et al., 2002), 
which may have contributed to the downregulation of DA neuron population activity. In support 
of its agonist-like activity at autoreceptors, a reduction in both the average firing rate and bursting 
activity in MAM rats was observed following 7d withdrawal from repeated treatment, although no 
significant reduction in firing rate or bursting was observed across the population of DA neurons 
recorded following acute ARI administration or following 21d repeated ARI treatment compared 
to VEH-treated rats. Several other in vivo studies have demonstrated ARI’s agonist-like activation 
at D2 autoreceptors (Kikuchi et al., 1995; Semba et al., 1995), including its ability to block 
increased DA synthesis in reserpine-treated rats (Kikuchi et al., 1995). No significant differences 
in average firing rate and bursting activity were observed across the total population of DA neurons 
recorded between ARI and vehicle-treated MAM rats in this study, but acute i.p. ARI 
administration has previously been shown to modestly reduce DA neuron firing rate and bursting 
activity (Bortolozzi et al., 2007; Dahan et al., 2009). Therefore, it may reduce DA neuron 
population activity through action on presynaptic D2 receptors to downregulate DA neuron 
activity. ARI’s proposed partial agonism, with lower intrinsic activity at the receptor than a full 
agonist, may also account for its antagonist-like effect at postsynaptic D2 receptors in animal 
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models of DA hyperactivity, such as blockade of apomorphine-induced hyperlocomotion and 
stereotypy (Kikuchi et al., 1995).  
It is difficult to conclude whether this accounts for ARI’s actions across a range of systems. 
It has been suggested from in vitro studies that ARI possesses functional selectivity with intrinsic 
activity dependent on the cellular environment of the receptor and the signaling pathway activated 
(Lawler et al., 1999; Shapiro et al., 2003; Mailman and Gay, 2004; Urban et al., 2007), which may 
contribute to its state-dependent effects. ARI may lack biased signaling in vivo, but it has served 
as a template for β-arrestin-biased D2 receptor ligands that have recently been studied as potential 
APD compounds to more effectively target both cortical and striatal DA dysfunction (Urs et al., 
2017). It is also possible that different factors may contribute to the reduction observed following 
acute and repeated treatment, and/or following withdrawal from repeated treatment. For example, 
DA neuron population activity also remains reduced following 1 week withdrawal from repeated 
haloperidol administration, but unlike the acute and repeated effects of haloperidol (Grace and 
Bunney, 1986; Valenti et al., 2011b), the reduction following withdrawal has been suggested to 
not due to depolarization block and may instead be due to the modulatory influence of other brain 
regions (Gill et al., 2014). Finally, ARI has a diverse receptor binding profile, including significant 
affinity for serotonin (5-HT)1A and 5-HT2A receptors (Jordan et al., 2002; Shapiro et al., 2003), 
and the potential influence of other neurotransmitter systems on DA neuron activity cannot be 
excluded. Additional in vivo studies are needed to determine the mechanisms underlying ARI's 
selective downregulation of DA neuron activity in MAM rats, such as whether it is due to action 
on presynaptic D2 receptors, and whether they can be generalized to all D2 receptor partial agonists. 
Furthermore, it remains to be determined why ARI selectively downregulates DA neuron activity 
in MAM rats and not in normal rats. 
48 
Removal of Haloperidol-Induced Depolarization Block by Aripiprazole 
Prevalent problems associated with APD treatment and withdrawal have driven a search 
for treatments with a more favorable side effect profile and improved efficacy across symptom 
domains. Novel target compounds for the treatment of schizophrenia have shown promise in 
preclinical research, but failed to show efficacy in clinical trials. However, preclinical research is 
typically performed on drug-naïve rats, whereas clinical trials are performed on patients that have 
received only brief withdrawal from years of prior APD treatment. We previously found that 
withdrawal from repeated HAL treatment produced persistent DA supersensitivity in MAM rats, 
interfering with the ability of a novel target compound to reduce amphetamine-induced 
hyperlocomotion in MAM rats (Gill et al., 2014). It is possible that DA supersensitivity following 
prior D2 antagonist treatment in patients with schizophrenia may similarly mask potential effects 
of novel target compounds in clinical trials, despite their promise in drug screening paradigms 
performed in normal, drug-naïve rodents. Prior evidence that repeated ARI administration may not 
upregulate D2 receptors or produce DA supersensitivity (Inoue et al., 1997; Tadokoro et al., 2011), 
unlike D2 receptor antagonists (O'Dell et al., 1990; See et al., 1990; Lidow and Goldman-Rakic, 
1994; Silvestri et al., 2000; Tadokoro et al., 2011), indicate that ARI may circumvent this potential 
confound. However, in patients taking D2 antagonist APDs, the switch to ARI is reported to result 
in a temporary worsening of psychotic symptoms, which was suggested to be unmasking of the 
increase in D2 receptors from prior treatment (Takase et al., 2015; Tadokoro et al., 2017). Indeed, 
the ability of ARI to reverse depolarization block in HAL-treated MAM rats demonstrated in the 
present study is consistent with the reported worsening in psychotic symptoms in patients upon 
transitioning to ARI from D2 antagonist drugs.  Thus, while ARI may not have superior efficacy 
in schizophrenia (Leucht et al., 2009a; Leucht et al., 2009b), it may be less likely to induce 
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persistent deleterious effects that can arise from a persistent elevation in DA sensitivity that occurs 
with D2 antagonists (Silvestri et al., 2000; Chouinard et al., 2017). 
Overall, this study demonstrates that ARI rapidly normalizes the hyperdopaminergic state 
observed in MAM rats without effect on DA neuron population activity in a normal system. In 
contrast to the action of D2 receptor antagonists, the reduction is unlikely due to depolarization 
block. Although it is unknown how ARI reduces DA neuron activity in MAM rats, it may act as 
an agonist on presynaptic receptors to downregulate spontaneous activity.  
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3.0 THE MGLUR2/3 AGONIST POMAGLUMETAD METHIONIL INDIRECTLY 
REGULATES DOPAMINE NEURON ACTIVITY VIA ACTION IN THE VENTRAL 
HIPPOCAMPUS 
3.1 INTRODUCTION 
APDs that target DA D2 receptors have remained the primary treatment for schizophrenia 
since their introduction in the 1950s (Kapur and Mamo, 2003). Their therapeutic effect is attributed 
to D2 receptor antagonist or partial agonist action (Creese et al., 1976; Kapur et al., 2000; Burris 
et al., 2002) that reduces elevated DA neuron activity (Grace and Bunney, 1986; Valenti et al., 
2011b; Sonnenschein et al., 2019). Dysregulated presynaptic DA neuron activity (Laruelle and 
Abi-Dargham, 1999; Howes et al., 2011a) is observed in patients with schizophrenia and correlated 
to positive symptom severity (i.e. hallucinations, delusions, thought disorder). Accordingly, 
patients who respond to current APDs primarily display a reduction in positive symptoms (Leucht 
et al., 2013). However, approximately 30% of patients with schizophrenia display treatment 
resistance with little or no response to standard treatment (Saha et al., 2005). Even clozapine, the 
treatment of choice for refractory symptoms, is ineffective in approximately 50% of patients who 
take it (Kane et al., 1988; Lieberman et al., 1994; Remington et al., 2005). Current APDs are also 
hindered by a high rate of treatment nonadherence, driven by factors including limited efficacy 
and poor tolerability (Lieberman et al., 2005). Furthermore, there is evidence of persistent and 
potentially detrimental changes to brain morphology (Ho et al., 2011) and the DA system (Lidow 
et al., 1997; Silvestri et al., 2000) with long-term use of D2 receptor antagonists. These 
shortcomings highlight the need for alternative strategies, including novel APD mechanisms.  
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One of the most promising novel target candidates was group II metabotropic glutamate 
receptors, comprised of mGluR2 and mGluR3 (mGluR2/3). mGluR2/3 are prominently expressed 
in limbic brain regions, where they are primarily localized presynaptically on glutamatergic 
terminals to negatively regulate glutamate release (Nicoletti et al., 2011). Aberrant excitatory-
inhibitory balance has been well-characterized in schizophrenia as an underlying component of 
numerous symptoms of schizophrenia (Benes and Berretta, 2001; Lewis et al., 2005), including a 
primary driver of DA dysregulation (Lodge and Grace, 2011). Despite extensive preclinical 
support for mGluR2/3 as a novel APD target (Rorick-Kehn et al., 2007; Mezler et al., 2010) and 
success in an early clinical trial (Adams et al., 2013), the mGluR2/3 agonist pomaglumetad 
methionil (POM) was pulled from phase III clinical trials for insufficient efficacy in reducing 
psychotic symptoms compared to current APDs (Marek, 2015). Later analyses found that POM 
was more effective in certain populations, including early-in-disease patients (Kinon et al., 2015), 
indicating that further research is necessary to clarify the disconnect between the preclinical 
research and clinical trial results.  
A critical question that needs to be addressed is how, if at all, mGluR2/3 agonists regulate 
DA neuron activity. Prior research on mGluR2/3 agonists primarily focused on the PFC 
(Moghaddam and Adams, 1998; Lorrain et al., 2003; Homayoun and Moghaddam, 2007; Pehrson 
and Moghaddam, 2010). Their potential therapeutic effect was suggested to be DA-independent 
due absence of mGluR2/3 expression in the VTA (Ohishi et al., 1993a; Ohishi et al., 1993b; Neki 
et al., 1996) and their lack of effect on DA levels at baseline or following VTA stimulation 
(Pehrson and Moghaddam, 2010). However, mGluR2/3 is densely expressed in the HPC, including 
the human anterior HPC (Blümcke et al., 1996) and corresponding rat vHPC (Ohishi et al., 1993a; 
Ohishi et al., 1993b). Patients with schizophrenia demonstrate a loss of PV+ interneuron regulation 
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of pyramidal neuron activity in the anterior HPC, associated with the onset of psychosis (Schobel 
et al., 2013; Heckers and Konradi, 2015). A similar progression of PV+ interneuron loss (Lodge 
et al., 2009) and vHPC hyperactivity (Lodge and Grace, 2007) is observed in MAM rats. The 
increased vHPC drive results in an increased number of spontaneously active DA neurons in the 
VTA, which produces a hyperdopaminergic state consistent with findings in patients (Modinos et 
al., 2015). MAM rats thus provide a clinically relevant model to determine how mGluR2/3 
activation may affect a system-wide disorder. This study aimed to determine the role of mGluR2/3 
in the regulation of DA neuron activity and our findings demonstrate that mGluR2/3 agonists act 
on a hyperactive vHPC to indirectly reduce increased DA neuron population activity in the VTA. 
3.2 METHODS 
Subjects  
All procedures were conducted in accordance with the National Institute of Health Guide 
for the Care and Use of Laboratory Animals and approved by the University of Pittsburgh 
Institutional Animal Care and Use Committee. Timed pregnant Sprague-Dawley dams (Envigo, 
Indianapolis, IN) were obtained on gestational day (GD)15 and MAM (20 mg/kg, i.p., Midwest 
Research Institute, Kansas City, MO) or saline (SAL; 1 ml/kg, i.p.) was administered on GD17. 
Male and female pups were weaned on postnatal day (PD)23. Naïve adult male rats were obtained 
from Envigo for restraint stress experiments. All rats were housed in groups of 2-3 with littermates 
in a temperature (22°C) and humidity (47%)-controlled facility with ad libitum food and water in 
a normal 12-h light-dark cycle. 
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Drug Administration  
LY2140023 (pomaglumetad methionil, POM), the prodrug of mGluR2/3 agonist 
LY404039, was obtained from Selleck Chemicals, Houston, TX. The mGluR2/3 antagonist 
LY341495 (LY34) was obtained from Tocris Bioscience, Minneapolis, MN. Both drugs were 
dissolved in 0.9% sterile saline and prepared at a volume of 1 ml/kg, except the 10 mg/kg dose of 
POM, which was mixed at a volume of 3 ml/kg for improved solubility. Drugs were dissolved 
with dropwise addition of 1M NaOH to POM (pH ~7) and LY34 (pH ~8) solutions. Vehicle 
(VEH)-treated rats received 0.9% sterile saline. All systemic treatments were administered 
intraperitonially. 
For electrophysiological experiments, POM or vehicle was administered to adult MAM 
and SAL rats following anesthetization and 30 minutes prior to electrophysiological recording. 
Recordings were performed within approximately 3-4 hours of administration. For female rat 
recordings, vaginal lavages were taken following anesthetization. Estrous stage was determined 
using a light microscope based on criteria described in (Marcondes et al., 2002; Hubscher et al., 
2005). To examine the effects of repeated POM administration on DA neuron activity, adult male 
MAM and SAL rats were randomly assigned to either acute or repeated administration groups and 
received either acute or 14d repeated daily i.p. administration of either POM or vehicle. On the 15th 
day, rats received a final treatment 30 min prior to electrophysiological recording.  
For acute, intra-vHPC microinfusions, rats were implanted ipsilateral to the side of the 
recording with 23-gauge guide cannula 1.0 mm dorsal to the ventral subiculum or ventral CA1 at 
-5.7 mm posterior and +4.6 mm lateral from bregma, and -6.0 mm ventral from the top of skull. 
0.5 µg of POM was gradually infused over 2 minutes at a volume of 0.5 µl through a 33-gauge 
injection cannula protruding 1.0 mm past the end of the implanted guide cannula. The injection 
 54 
cannula was left in place for 1 minute to ensure diffusion of drug into the surrounding tissue. The 
control group consisted of rats that received vehicle infusion into the vHPC. Recordings took place 
until approximately 2-3 h after infusion. 
Electrophysiological Recordings 
The activity state of DA neurons in the VTA was measured using in vivo extracellular 
recordings. Rats were anesthetized with chloral hydrate (400 mg/kg; i.p.) and placed on a 
stereotaxic frame (Kopf, Tujunga, CA). Supplemental anesthesia was administered i.p. to maintain 
suppression of the hind limb withdrawal reflex. Body temperature was maintained at 37°C with a 
temperature-controlled heating pad (CWE Inc., Ardmore, PA). Single-barrel glass electrodes 
(WPI, Sarasota, FL) were pulled vertically (PE-2, Narasige, Japan), broken under a microscope to 
an impedance of 6-8 MΩ, and filled with 2 M NaCl containing 2% Chicago Sky Blue dye in 2 M 
saline. Electrodes were lowered with a hydraulic micropositioner (Kopf) to sample the VTA: AP: 
-5.3 to -5.7 mm and ML: 0.6 to 1.0 mm from bregma, DV: -6.5 to -9.0 mm from the top of brain). 
Recordings were performed by making 6-9 vertical electrode passes (“tracks”) in a predetermined 
grid pattern with each track separated by 0.2 mm. Single-unit activity was obtained using an 
amplifier (Fintronics, Orange, CT) using a highpass filter at 30 Hz and lowpass at 16 kHz. DA 
neurons were classified based on established criteria, including a biphasic action potential with 
duration >2.2 ms, 1-10 Hz firing rate, and irregular and burst firing patterns with the burst initiation 
defined as in interspike interval of ≤ 80 msec and termination as >160 msec (Grace and Bunney, 
1983; Grace and Bunney, 1984; Ungless and Grace, 2012). The activity of each DA neuron was 
recorded for at least 1 minute of stable spontaneous activity using LabChart software (AD 
Instruments, Colorado Springs, CO).  
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At the end of each recording, electrode placement was verified following each experiment 
via electrophoretic ejection of Chicago Sky Blue dye from the tip of the recording electrode (-20 
µA constant current, 20 min). Rats were then overdosed with chloral hydrate and decapitated. The 
brains were removed and fixed for at least 48 hours (8% paraformaldehyde in PBS), cryoprotected 
(25% sucrose in PBS) until saturated, and sliced on a cryostat into 60µm sections, which were 
mounted onto gelatin-coated slides. Slides were stained with a mixture of cresyl violet and neutral 
red for verification of electrode sites with reference to a stereotaxic atlas (Paxinos and Watson, 
2007).  
Electrophysiological Recording Analysis 
Three parameters were analyzed for DA neuron activity: (1) the average number of 
spontaneously active DA neurons encountered per electrode track (“population activity”), (2) 
average firing rate and (3) the percentage of spikes that occurred in bursts (%SIB). Analysis of 
firing rate and bursting activity was performed using NeuroExplorer (Plexon, Dallas, TX). 
Population activity was averaged within each animal and then across animals in each group, 
whereas the firing rate and burst activity of each neuron was counted as an independent replicate 
and averaged across animals in a group. Significance was assessed with a two-way ANOVA 
(MAM x Treatment or Condition x Treatment) followed by Tukey post-hoc comparisons using 
GraphPad Prism 8 (GraphPad Software, San Diego, CA). Three-way ANOVA (MAM x Treatment 
x Time) was completed with SAS (SAS Institute, Cary, NC) to examine effects of acute vs repeated 
treatment. 
Novel Object Recognition 
The novel object recognition (NOR) test was conducted in a rectangular test box (L70 x 
W40 x H30 cm). Each rat was habituated to the box for 10 minutes one day prior to the test. The 
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test day involved two 5 min trials separated by a 1 h intertrial interval. Rats received a randomized 
injection of either VEH (1 ml/kg) or POM (1 mg/kg or 3 mg/kg), i.p. 30 minutes prior to the first 
trial. In the first trial (T1), rats were placed in the box containing two identical objects. In the 
second trial (T2), one of the objects presented in T1 was replaced by a novel object. The familiar 
and novel objects were too heavy to be displaced by the animals and had different shape, color and 
texture. The box and the objects were cleaned between each trial. Habituation and behavioral tests 
were performed during the dark cycle. The behavior was recorded on video and object interaction 
was scored by an experimenter blinded to treatment group. Interaction time (s) of each object in 
each trial was recorded manually by the use of stopwatches and defined as time when the rat 
interacts directly with the object, such as licking, sniffing, or touching it with its forepaws. 
Recognition memory was assessed using the discrimination index (discrimination index = (novel 
– familiar / novel + familiar)), corresponding to the difference between the time exploring the
novel and the familiar object, corrected for total time exploring both objects. Two-way ANOVA 
was used to compare the differences between MAM and SAL groups, drug treatment, and the 
possible interaction between MAM and treatment on behavioral measures. Tukey’s post-hoc 
comparisons were conducted for significant main effects. All statistics were calculated using 
Graphpad Prism 8. 
Restraint Stress 
Rats were restrained for 2 h in custom made Plexiglas cylinder restraint tubes (internal 
diameter 6 cm with length adjusted to rat size), placed in a ventilated transport tub. Rats in the 
control condition remained in their home cage for 2 h. Rats were randomly assigned to receive 
vehicle (1 ml/kg) or POM (3 mg/kg), i.p., 30 min prior to the stress or control condition. A subset 
of POM-treated rats received pretreatment with LY34 (1 mg/kg, i.p.) 15 min prior to the POM 
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injection. In vivo electrophysiological recordings of DA neuron activity were performed in 
anesthetized rats immediately following the restraint/control condition.  
3.3 RESULTS 
3.3.1 Pomaglumetad Dose-Dependently Reduces DA Neuron Activity in MAM Rats 
Electrophysiological recordings of DA neuron activity in the VTA were conducted from 
MAM rats and SAL rats that were pretreated with POM or VEH. VEH-treated MAM rats (n = 7 
rats, 85 neurons) exhibited the anticipated elevation in population activity with an average of 1.8 
± 0.1 cells/track compared to VEH-treated SAL rats (n = 6 rats, 49 neurons), which had an 
average of 0.9 ± 0.1 cells/track (Fig. 3-1 A; 2-way ANOVA main effects: for MAM, F(1,43) = 
9.249,  p = 0.004; for POM, F(3,43) = 3.005, p = 0.041; for MAM-by-POM interaction: F(3,43) = 
18.21, p < 0.001; post hoc MAM control vs SAL control: p < 0.001). POM significantly reduced 
DA neuron population activity in MAM rats, at 1 mg/kg (n = 6 rats, 68 neurons; post hoc 
MAM control vs MAM 1 mg/kg: p = 0.019), 3 mg/kg (n = 7 rats, 61 neurons; post hoc MAM 
control vs MAM 3 mg/kg: p = 0.007) and 10 mg/kg (n = 6 rats, 38 neurons; post hoc MAM 
control vs MAM 10 mg/kg: p = 0.001) compared to VEH-treated MAM rats. There was also a 
significant reduction in DA neuron population activity between 1 mg/kg and 10 mg/kg in MAM 
rats (post hoc MAM 1 mg/kg vs MAM 10 mg/kg: p = 0.003). In contrast, there was no reduction 
in DA neuron population activity in POM-treated SAL rats, at 1 mg/kg (n = 7 rats, 46 
neurons) or 3 mg/kg (n = 6, 48 neurons), with a significant increase in population activity at 
10 mg/kg (n = 6 rats, 58 neurons; post hoc SAL control vs SAL 10 mg/kg: p = 0.010), compared 
to VEH-treated SAL rats (Fig 3-1A). There was no significant change in firing rate (Fig. 3-1 B) or 
bursting (Fig. 3-1 C) with POM treatment compared to VEH treatment in MAM or SAL rats.  
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A separate cohort of MAM and SAL rats were treated with either acute or repeated POM 
or VEH (Fig 3-1 D; 3-way ANOVA main effects: for MAM F(1,52) = 20.38,  p < 0.001; for POM, 
F(1,52) = 14.82, p < 0.001; for MAM-by-POM interaction: F(1,52) = 11.82, p < 0.001). Compared 
to their respective VEH-treated group, POM-treated MAM rats showed a significant reduction in 
DA neuron population activity for both acute POM (n = 6 rats, 52 neurons; p = 0.002) and repeated 
POM (n = 9 rats, 69 neurons; p = 0.011). There was no significant difference between MAM rats 
treated acutely vs repeatedly with POM (p > 0.999) or MAM rats treated acutely vs repeatedly 
with VEH (p = 0.950). There were no significant differences in SAL rat DA neuron population 
activity across treatment and time groups (Fig 3-1 D). There were also no significant differences 
in firing rate (Fig 3-1 E) or bursting activity (Fig 3-1 F) of the DA neurons across all groups.  
The effect of acute POM administration on DA neuron activity was examined in female 
MAM (Fig 3-1 G; 2-way ANOVA main effects: for POM F(1,26) = 12.64, p = 0.001; for Estrous 
F(1,26) = 9.213, p = 0.005) and SAL rats split into proestrous/estrous or metestrous/diestrous 
groups based on cell composition and density from vaginal gavage based on previously described 
criteria. Female MAM rats in estrous/proestrous treated with VEH (n = 7 rats, 79 neurons) 
displayed significantly greater DA neuron population activity compared to female MAM rats in 
metestrous/diestrous (Fig 3-1 H; n = 7 rats, 53 neurons; p = 0.037). MAM rats in estrous/proestrous 
treated with POM (n = 8 rats, 48 neurons) displayed significantly fewer spontaneously active DA 
neurons compared to MAM rats in estrous/proestrous treated with VEH (Fig 3-1 H; p = 0.012). 
MAM rats in metestrous/diestrous treated with POM (n = 8 rats, 40 neurons) did not display a 
significant difference in DA neuron population activity compared to VEH (Fig 3-1 H; p = 0.354). 
Female SAL rats displayed a main effect of estrous stage (Fig 3-1 H; 2-way ANOVA main effects: 
for Estrous F(1,25) = 8.411, p = 0.008), but no main effect of POM treatment between SAL rats 
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in estrous/proestrous treated with VEH (n = 7 rats, 67 neurons) or POM (n = 7 rats, 60 neurons) 
and SAL rats in metestrous/diestrous treated with VEH (n = 7 rats, 30 neurons) or POM (n = 8 
rats, 47 neurons). There were no significant differences in firing rate or bursting activity of DA 
neurons in female rats across conditions. 
3.3.2 Intra-Ventral Hippocampal Infusion of Pomaglumetad is Sufficient to Reduce DA 
Neuron Activity in MAM Rats 
Electrophysiological recordings of DA neuron activity in the VTA were conducted 
following infusion of either POM or VEH in the vHPC of MAM and SAL rats (Fig 3-2 A). MAM 
rats that received a VEH infusion (n = 7 rats, 75 neurons) displayed significantly higher DA neuron 
population activity compared to VEH-treated SAL rats (Fig 3-2 B; n = 7 rats, 51 neurons; 2-way 
ANOVA main effects: for MAM, F(1,26) = 19.16,  p = 0.002; for POM, F(1,26) = 13.17, p = 
0.001; post hoc MAM VEH vs SAL VEH: p = 0.001). MAM rats that received a POM infusion (n 
= 9 rats, 72 neurons) displayed a significant reduction in DA neuron population activity compared 
to untreated MAM rats (p = 0.002). POM treatment did not significantly affect DA neuron activity 
in SAL rats (Fig 3-2 B). There were no significant differences in the firing rate of DA neurons 
across groups (Fig 3-2 C) and a main effect of POM on % of spikes in burst (Fig 3-2 D; F(1,224) 
= 5.191, p = 0.024). 
3.3.3 Pomaglumetad Increases Novel Object Recognition in MAM Rats 
MAM rats pretreated with VEH displayed reduced interaction with a novel object 
compared to a familiar object, as measured by a discrimination index ((novel-
familiar)/(novel+familiar)), compared to SAL rats treated with VEH (Fig 3-3 A; 2-way ANOVA 
main effects: for MAM: F(2,48) = 8.505, p = 0.005, for MAM-by-POM interaction: F(2,48) =
60 
 4.188, p < 0.021; post hoc MAM VEH vs SAL VEH: p = 0.003). MAM rats treated with 1 mg/
kgdid not significantly improve NOR compared to VEH, but MAM rats treated with 3 mg/kg
showed a significant increase in discrimination index compared to VEH-treated MAM rats (p = 
0.035). There was no significant effect of POM on discrimination index in SAL rats (Fig 3-3 A). 
MAM rats treated with 3 mg/kg SAL displayed a significant reduction in time exploring either 
object in the test phase compared to VEH-treated SAL rats (Fig 3-3 B; 2-way ANOVA main 
effect for POM: F(2,48) = 9.118, p < 0.001, post hoc SAL VEH vs SAL 3mg/kg: p = 0.003).  
3.3.4 Pomaglumetad Blocks Restraint Stress-Induced Increase in DA Neuron Activity 
 Rats that were treated with VEH prior to acute restraint stress (n = 6 rats, 88 
neurons) displayed a significant increase in DA neuron activity in the VTA in 
electrophysiological recordings performed immediately following stress (Fig. 3-4 A; 2-way 
ANOVA main effects: for Treatment, F(2,30) = 8.799,  p = 0.001; for Stress, F(1,30) =35.360, p 
< 0.001; for Treatment-by-Stress interaction: F(2,30) = 5.765, p < 0.008; post hoc VEH stress vs 
VEH control: p < 0.001), compared to rats that were treated with VEH and left in their home 
cage (n = 6 rats, 57 neurons). Rats that were treated with POM prior to acute restraint stress (n = 
6 rats, 50 neurons) displayed a significant reduction in DA neuron population activity compared 
to stressed rats that were treated with VEH (p < 0.001). The effect of POM on DA neuron 
population activity in stressed rats was blocked by pretreatment with both POM and the 
mGluR2/3 antagonist LY34 (n = 6 rats, 64 neurons; p = 0.02). Rats that were stressed that 
received both POM+LY34 did not display a significant difference in DA neuron population 
activity compared to stressed rats that were treated with VEH (p = 0.694). There was no 
significant effect of treatment on DA neuron activity in rats that were kept in their home cage 
(Fig 3-4 A). There were also no significant effects in firing rate (Fig 3-4 B) or the % of spikes in 
burst (Fig 3-4 C).    
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Figure 3-1: Pomaglumetad dose-dependently reduces DA neuron population activity in MAM rats 
(A) 30 min following POM i.p., MAM rats displayed a dose depenent reduction in the number of spontaneously
active DA neurons in the VTA compared to MAM rats that received VEH, which was not observed in SAL rats. 
There were no significant differences in the firing rate (B) or percentage of spikes in bursts (C) between POM and 
VEH administration in MAM or SAL rats. (D) There was no tolerance in the reduction in DA neuron population 
activity following 14d repeated POM treatment in MAM rats, compared to acute treatment. There were no 
significant differences in the firing rate (E) or percentage of spikes in bursts (F) following either acute or repeated 
treatment in MAM or SAL rats. (G) Example pictures of proestrous (high density of nucleated cells and conified 
cells), estrous (high density of cornified cells with leukocytes), metestrous (low density of cell debris, few cornified 
cells) and diestrous (low density of leukocytes and nucleated cells) (H) MAM rats displayed higher DA neuron 
population activity in estrous/proestrous compared to diestrous/metestrous. 30 min following POM i.p., MAM rats 
in estrous/proestrous displayed a reduction in DA neuon population activity (I) ) SAL rats displayed higher DA 
neuron population activity in estrous/proestrous compared to diestrous/metestrous with no significant effect of POM 
administration. *p<0.05 **p<0.01 ***p<0.001 within groups #p<0.05 ##p<0.01 ###p<0.001 between groups. 
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Figure 3-2: Intra-ventral hippocampal infusion of pomaglumetad is sufficient to reduce DA neuron activity in 
MAM rats 
(A) Placements of cannula for vHPC infusion for MAM-VEH    MAM-POM    SAL-VEH    SAL-POM   (B)
Infusion of  POM in the vHPC was sufficient to reduce DA neuron population activity in MAM rats, which was not 
observed in SAL rats (C-D) no effect of intra-vHPC POM infusion on firing rate or the percentage of spikes in burst. 
*p<0.05 **p<0.01 ***p<0.001 within groups #p<0.05 ##p<0.01 ###p<0.001 between groups.
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Figure 3-3: Pomaglumetad increases novel object recognition in MAM rats 
(A) MAM rats treated with VEH, i.p. spent less time interacting with a novel object compared to a familiar object as
measured by a discrimination index ((novel-familiar)/(novel+familiar)) compared to SAL rats. MAM rats treated 
with 3 mg/kg, i.p. POM spent more time investigating the novel object compared to VEH treated MAM rats. There 
was no effect of POM on discrimination index in SAL rats. (B) POM reduced locomotor activity, measured by total 
time exploring objects in the test phase, which was significantly reduced in SAL rats treated with 3 mg/kg POM, 
i.p., compared to VEH-treated SAL rats. *p<0.05 **p<0.01 ***p<0.001 within groups #p<0.05 ##p<0.01
###p<0.001 between groups. 
Figure 3-4: Pomaglumetad blocks restraint stress-induced increase in DA neuron activity 
(A) Normal rats exposed to 2h acute restraint stress following VEH pretreatment displayed increased DA neuron
population activity compared to VEH-treated rats left in their home cage for 2h. POM pretreatment (3 mg/kg, i.p.) 
normalized DA neuron population activity in rats that received restraint stress to control levels, which was not 
observed in rats that received both POM and the mGluR2/3 antagonist LY34 prior to restraint stress. (B-C) No 
significant changes were observed in DA neuron firing rate or percentage of spikes in bursts. *p<0.05 **p<0.01 
***p<0.001 within groups #p<0.05 ##p<0.01 ###p<0.001 between groups. 
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3.4 DISCUSSION 
mGluR2/3 Agonists Regulate Dopamine Neuron Population Activity in MAM Rats 
Our work demonstrates that the mGluR2/3 agonist, POM, decreases VTA DA neuron 
population activity in MAM rats via action in the vHPC. Previous studies that have examined the 
effects of mGluR2/3-targeting drugs on DA release have produced conflicting results. Some have 
shown that mGluR2/3 agonists do not affect striatal DA release at baseline (Moghaddam and 
Adams, 1998; Pehrson and Moghaddam, 2010), which is consistent with the lack of effect we 
observed, in general, on DA neuron population activity in SAL rats and normal rats in baseline 
conditions. Others have found that mGluR2/3 agonists can reduce striatal DA release (Hu et al., 
1999,) and that mGluR2/3 antagonist administration can increase striatal DA release at baseline 
(Karasawa et al., 2006). In contrast, others have found that mGluR2/3 agonist administration 
produces an increase in striatal DA release at basal conditions (Ohno and Watanabe, 1995; Verma 
and Moghaddam, 1998). Differing effects may relate to differences in microdialysis procedure, the 
potency and specificity of the drug used, or drug dose. Though mGluR2/3 are primarily located 
presynaptically on glutamatergic neurons to negatively regulate excess glutamate release, there are 
also receptors located postsynaptically and on glial cells (Nicoletti et al., 2011), which can make 
dose an important factor (Jin et al., 2017). This may explain the observed significant increase in 
DA neuron population activity in SAL rats at the highest dose tested (10 mg/kg). Overall, our 
results indicate that mGluR2/3 agonists have the potential to reduce DA release through regulation 
of DA neuron population activity. However, this was only observed in states of increased DA 
neuron population activity driven indirectly by increased glutamate release from the vHPC.   
We also observed a significant reduction in DA neuron population activity in POM-treated 
female MAM rats, but the effect was dependent on estrous cycle stage. In both MAM and SAL 
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rats, we observed differences in DA neuron population activity across the estrous cycle. In 
proestrous/estrous, and particularly in late proestrous/early estrous, we observed a significant 
increase in DA neuron population activity in MAM and SAL females compared to population 
activity in metestrous/diestrous. This is consistent with results observed by others in female MAM 
rats (Perez et al., 2014) and changes in DA release and DA-dependent behavior observed in normal 
female rats across the estrous cycle (Castner et al., 1993; Xiao and Becker, 1994). Interestingly, 
POM only significantly reduced the increased DA neuron population activity during 
proestrous/estrous in MAM rats.  
Effects of mGluR2/3 Agonists Beyond the Hippocampus 
Intra-vHPC infusion of POM was sufficient to reduce DA neuron population activity. The 
effects of POM were not tested in the NAc, but due to the glutamatergic projections that the NAc 
receives from the vSub (Floresco et al., 2001), there is a reasonable chance that an intra-NAc 
infusion of POM would produce a similar effect. We hypothesize that regulation of excess 
glutamate anywhere within the circuit that regulates DA neuron population activity would be 
sufficient to affect DA neuron activity. 
Though the present study focused on the action of POM in the vHPC, following systemic 
treatment, POM would act in all brain regions that express mGluR2/3 receptors. mGluR2/3 
receptors are located in numerous cortical and limbic brain regions, including the PFC and the 
amygdala (Ohishi et al., 1993b; Ohishi et al., 1993a; Neki et al., 1996). POM’s regulation of 
glutamate release in these regions would have widespread effects on related circuits and behavior, 
and such circuit effects have the potential to affect other symptoms of schizophrenia (Fig. 3-5 A-
B).  
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Behavioral Tests of mGluR2/3 Action 
We found that pretreatment with POM dose-dependently improved the performance of 
MAM rats in NOR. MAM rats have previously been shown to display reduced NOR compared to 
SAL rats (Gomes and Grace, 2016), which may relate to impairment of HPC function. NOR is 
considered a working memory task when there is a short delay between the two trials. However, it 
has been shown to be HPC-dependent when there is a long delay, such as the 1 h used between 
trials in the present task (Hammond et al., 2004). We observed improvement in NOR despite the 
acute, dose-dependent decrease in spontaneous locomotor activity following POM administration 
(Rorick-Kehn et al., 2007). The reduction in locomotor activity, measured by total time exploring 
objects, only remained significant in the 2nd trial of SAL rats treated with the 3 mg/kg dose. 
Alterations in spontaneous locomotor behavior must be considered when interpreting locomotor-
based behaviors, such as amphetamine induced hyperlocomotion. POM may reduce movement 
regardless of effects on DA release. Thus, it effects on baseline locomotor activity may confound 
behavioral results and thus must be accounted for by a normalized measure to baseline.  
Prevention of Stress-Induced Increase in DA Neuron Activity 
The effects of POM on normalizing increased DA neuron population activity were not 
specific to the MAM model, but also observed in normal rats exposed to restraint stress. It has 
previously been shown acute restraint stress increases vHPC activity, which then drives increased 
DA neuron population activity (Valenti et al., 2011a). Our results replicated this finding and, 
accordingly, pretreatment with POM prevented the restraint stress-induced increase in DA neuron 
activity. POM has similarly been found to reduce increased vHPC activity in an elevated plus maze 
task (Linden et al., 2004). POM’s reduction of vHPC activity and DA neuron population activity 
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following stress may contribute to its anxiolytic-like effects found in other studies (Helton et al., 
1998; Kłodzińska et al., 1999; Shekhar and Keim, 2000; Spooren et al., 2002; Linden et al., 2004).   
Overall, our results show that POM can normalize DA neuron population activity in 
conditions of either transient or chronic pathological increased HPC activity and that its direct 
action in the vHPC is sufficient to produce this effect. However, it is important to note that our 
results do not indicate that its therapeutic action is identical to D2-targeting APDs or that its 
potential therapeutic benefits are limited to treating symptoms related to DA system dysregulation. 
For example, some patients who are treatment resistant do not show increased striatal DA synthesis 
capacity or release, but do demonstrate elevated glutamate levels in the anterior cingulate 
(Demjaha et al., 2014; Mouchlianitis et al., 2015). Therefore, patients who do not respond to D2-
targeting APDs may benefit from a drug that regulates glutamate levels. Better understanding of 
how mGluR2/3 agonists function mechanistically, particularly in clinically-relevant states, may 
provide better insight into their potential as a therapeutic target.  
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Figure 3-5: A proposed model for antipsychotic drug effects on symptom domains of schizophrenia 
(A) In schizophrenia, a hyperactive and dysrhythmic limbic hippocampus (HPC) contributes to positive symptoms
through its indirect regulation of DA activity in the ventral tegmental area (VTA), which projects to the associative 
striatum. It also contributes to negative and cognitive symptoms through its disruption of activity patterns with 
regions including the prefrontal cortex (PFC) and amygdala. All current antipsychotic drugs (APDs) act on D2 
receptors in the striatum, which results in a reduction in positive symptoms, but produce minimal benefit on 
cognitive symptoms or negative symptoms. (B) Compounds that reduce hypermetabolism in the limbic HPC by 
either increasing function of parvalbumin positive interneurons (PVI) or reducing the activity of pyramidal neurons 
(Pyr) should normalize hippocampal output and thereby may be more beneficial in treating all symptom domains of 
schizophrenia. 
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4.0 PERIPUBERTAL TREATMENT WITH MGLUR2/3 AGONIST PREVENTS 
DOPAMINE SYSTEM HYPERACTIVITY IN ADULTHOOD IN THE MAM MODEL 
OF SCHIZOPHRENIA 
4.1 INTRODUCTION 
Schizophrenia is a chronic and debilitating disorder that often emerges in late adolescence 
and early adulthood and is characterized by psychosis and a broad range of other cognitive and 
behavioral symptoms (Fatemi and Folsom, 2009; Tandon et al., 2013). A longer DUP is associated 
with a worse functional outcome, including poor response to APD treatment and greater risk of 
relapse (McGorry et al., 2009). Therefore, it is critical that those experiencing “first-episode 
psychosis” (FEP) receive rapid and effective treatment (Tandon et al., 2013). Existing treatments 
are effective in alleviating psychotic symptoms in many patients, but there remains an unmet need 
for early-intervention treatments that may improve symptoms long term by targeting early 
neuropathological processes (McGorry et al., 2009; Krystal and Anticevic, 2015) 
The prodromal phase is characterized by a period of sub-clinical symptoms in the years 
prior to the onset of FEP. Based on a clinical staging model (Wood et al., 2011; Fusar-Poli et al., 
2012), it consists of nonspecific symptoms such as depression, anxiety, and social withdrawal, 
followed by the emergence of attenuated psychotic symptoms, cognitive disturbances, and overall 
functional decline. Psychotic symptoms generally begin after puberty and are progressive in 
severity (Häfner et al., 1993). Accumulating research has suggested that puberty may serve a 
critical period surrounding the first episode and targeting pathophysiological processes during this 
time may provide long-term amelioration of symptoms. The maturational processes involved in 
puberty can shape brain development to support the alterations in physiological and behavioral 
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processes across adolescence (Sisk and Foster, 2004). When combined with genetic risk, these 
dynamic neurobiological changes are thought to contribute to the vulnerability of the developing 
brain to environmental factors that can lead to the emergence of psychiatric disorders. This may 
account for why adolescence is a period of peak onset for many psychiatric disorders, including 
schizophrenia (Kessler et al., 2005). Prior work with the MAM neurodevelopmental model, which 
demonstrates a number of phenotypes relevant to schizophrenia (Modinos et al., 2015), has shown 
that pharmacological treatments administered during puberty can prevent pathological phenotypes 
in adulthoods. Based on the critical role of stress in the development of schizophrenia (Corcoran 
et al., 2003; Holtzman et al., 2013), MAM rats were treated with daily administration of the 
anxiolytic drug diazepam peri-pubertally (PD 31–40), which prevented the emergence of the 
hyperdopaminergic state, anxiety-like behavior and the higher neuronal firing rates within the 
basolateral amygdala normally present in adult MAM rats (Du and Grace, 2013, 2016b). These 
findings indicate that alleviating anxiety and abnormal stress responsivity during puberty 
prevented the transition to the schizophrenia-like phenotype in adult MAM rats. Similarly, 
prodromal interventions may prevent the progression of psychosis in at-risk individuals (McGorry 
et al., 2009).  
Patients  with schizophrenia and animal models have demonstrated a reduction in PV+ 
GABA interneuron function, which is associated with an imbalance between excitatory and 
inhibitory neurotransmission (Lodge et al., 2009; Konradi et al., 2011; Lewis et al., 2012; Heckers 
and Konradi, 2015). Altered glutamatergic transmission in in the HPC, in particular, is prominently 
observed in the transition to psychosis (Schobel et al., 2013; Poels et al., 2014a). A hyper-
metabolic state of the HPC, mimicked in an animal model with chronic ketamine exposure, was 
associated with PV+ GABAergic interneuron dysfunction, increased glutamate levels, and 
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reduction in volume in the HPC (Schobel et al., 2013). Based on human and animal model studies, 
these alterations appear to lead to increased subcortical DA function, especially in the associative 
striatum, which becomes progressively more pronounced as CHR individuals transition to 
psychosis, along with further loss of HPC volume (Lodge and Grace, 2007; Kegeles et al., 2010; 
Howes et al., 2011a). The protection of excitatory-inhibitory circuits within the HPC therefore 
demonstrates potential for preventative treatment against the emergence of DA system 
dysfunction.  
Group II metabotropic glutamate receptors (mGluR2/3) showed promise in preclinical 
research as a target to treat the aberrant excitatory-inhibitory balance implicated as a central 
component of the development and pathophysiology of schizophrenia (Rorick-Kehn et al., 2007; 
Mezler et al., 2010). The mGluR2/3 pomaglumetad methionil (POM) was pulled from phase III 
clinical trials (Adams et al., 2014; Marek, 2015), though later analyses found that early-in-disease 
patients treated with POM demonstrated significant improvement in symptoms, which was not 
observed in late-in-disease patients (Kinon et al., 2015). This contributed to questions that have 
been raised in recent years about whether regulating glutamatergic dysfunction early in the disease 
may be particularly useful in treating symptoms (Krystal and Anticevic, 2015; Lieberman et al., 
2019).  Based on previous work (see Chapter 3) POM can indirectly regulate DA neuron activity 
by normalizing increased activity in the vHPC. We therefore aimed to determine whether of 
peripubertal administration of POM can prevent vHPC dysfunction and increased DA neuron 
population activity observed in adult MAM rats.  
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4.2 METHODS 
Subjects  
All procedures were conducted in accordance with the National Institute of Health Guide 
for the Care and Use of Laboratory Animals and approved by the University of Pittsburgh 
Institutional Animal Care and Use Committee. Timed pregnant Sprague-Dawley dams (Envigo, 
Indianapolis, IN) were obtained on gestational day (GD)15 and MAM (20 mg/kg, i.p., Midwest 
Research Institute, Kansas City, MO) or saline (SAL; 1 ml/kg, i.p.) was administered on GD17. 
Male and female pups were weaned on postnatal day (PD)23. Naïve adult male rats were obtained 
from Envigo for restraint stress experiments. All rats were housed in groups of 2-3 with littermates 
in a temperature (22°C) and humidity (47%)-controlled facility with ad libitum food and water in 
a normal 12-h light-dark cycle.  
Drug Administration 
LY2140023 (pomaglumetad methionil, POM), the prodrug of mGluR2/3 agonist 
LY404039, was obtained from Selleck Chemicals, Houston, TX and dissolved in 0.9% sterile 
saline with dropwise addition of 1M NaOH to POM (pH ~7) at a volume of 1 ml/kg. Vehicle 
(VEH)-treated rats received 0.9% sterile saline. Peripubertal treatments occurred from PD31-40. 
All rats were weighed daily and received 3 mg/kg POM (i.p.), 1 ml/kg vehicle (i.p.) or no injection.  
Electrophysiological Recordings   
In vivo extracellular recordings occurred on either PD 47-56 (“early adulthood”) or PD 83-
96 (“late adulthood”). Rats were anesthetized with chloral hydrate (400 mg/kg; i.p.) and placed on 
a stereotaxic frame (Kopf, Tujunga, CA). Supplemental anesthesia was administered i.p. to 
maintain suppression of the hind limb withdrawal reflex. Body temperature was maintained at 
37°C with a temperature-controlled heating pad (CWE Inc., Ardmore, PA). Single-barrel glass 
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electrodes (WPI, Sarasota, FL) were pulled vertically (PE-2, Narasige, Japan), broken under a 
microscope to an impedance of 6-8 MΩ, and filled with 2 M NaCl containing 2% Chicago Sky 
Blue dye in 2 M saline. Electrodes were lowered with a hydraulic micropositioner (Kopf) to sample 
neural activity in the region of interest. Single-unit activity was obtained using an amplifier 
(Fintronics, Orange, CT) using a highpass filter at 30 Hz and lowpass at 16 kHz. Neural activity 
was recorded for at least 1 minute of stable spontaneous activity using LabChart software (AD 
Instruments, Colorado Springs, CO). At the end of each recording, electrode placement was 
verified following each experiment via electrophoretic ejection of Chicago Sky Blue dye from the 
tip of the recording electrode (-20 µA constant current, 20 min). Rats were then overdosed with 
chloral hydrate and decapitated. The brains were removed and fixed for at least 48 hours (8% 
paraformaldehyde in PBS), cryoprotected (25% sucrose in PBS) until saturated, and sliced on a 
cryostat into 60µm sections, which were mounted onto gelatin-coated slides. Slides were stained 
with a mixture of cresyl violet and neutral red for verification of electrode sites with reference to 
a stereotaxic atlas (Paxinos and Watson, 2007). 
Ventral Tegmental Area 
Recordings were performed by making 6-9 vertical electrode passes (“tracks”) in a 
predetermined grid pattern with each track separated by 0.2 mm (AP: -5.3 to -5.7 mm and ML: 0.6 
to 1.0 mm from bregma, DV: -6.5 to -9.0 mm from the top of brain). DA neurons were classified 
based on established criteria, including a biphasic action potential with duration >2.2 ms, 1-10 Hz 
firing rate, and irregular and burst firing patterns with the bursts characterized by an interspike 
interval of 80-160ms (Grace and Bunney, 1983; Grace and Bunney, 1984; Ungless and Grace, 
2012).  
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Ventral Hippocampus 
Recordings were performed by making 6 electrode tracks as described above, with 
coordinates AP: -5.5 to -5.9 mm and ML: 4.6 to 5.0 mm from bregma, DV: -5.5 to -8.5 mm from 
the top of brain. Neurons with a wide biphasic action potential duration >2.0 ms and ≤2.0 Hz 
firing rate were classified as putative pyramidal neurons. Burst firing was characterized by at 
least two spikes with an interspike interval of 80-160ms.  
Electrophysiological Recording Analysis 
Three parameters were analyzed for DA neuron activity: (1) the average number of 
spontaneously active DA neurons encountered per electrode track (“population activity”), (2) 
average firing rate and (3) the percentage of spikes that occurred in bursts (%SIB). Firing rate 
and %SIB were analyzed for pyramidal neurons. Analysis of firing rate and bursting activity 
was performed using NeuroExplorer (Plexon, Dallas, TX). Population activity was averaged 
within each animal and then across animals in each group, whereas the firing rate and burst 
activity of each neuron was counted as an independent replicate and averaged across animals 
in a group. Significance was assessed with a two-way ANOVA (MAM x Treatment) followed by 
Tukey post-hoc comparisons. 
Novel Object Recognition 
Novel Object Recognition (NOR) was performed on PD 47-48 or PD 83-84. Each rat was 
habituated to a rectangular box (L70 x W40 x H30 cm) for 10 minutes one day prior to the test. 
The test day involved two 5 min trials separated by a 1 h intertrial interval. Rats received a 
randomized injection of either VEH (1 ml/kg) or POM (1 mg/kg or 3 mg/kg), i.p. 30 minutes prior 
to the first trial. In the first trial (T1), rats were placed in the box containing two identical objects. 
In the second trial (T2), one of the objects presented in T1 was replaced by a novel object. The 
familiar and novel objects were too heavy to be displaced by the animals and had different shape, 
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color and texture. The box and the objects were cleaned between each trial. Habituation and 
behavioral tests were performed during the dark cycle. The behavior was recorded on video and 
object interaction was averaged between two experimenters blinded to treatment group. Interaction 
time (s) of each object in each trial was recorded manually by the use of stopwatches and defined 
as time when the rat interacts directly with the object, such as licking, sniffing, or touching it with 
its forepaws. Recognition memory was assessed using the discrimination index (discrimination 
index = (novel – familiar / novel + familiar)), corresponding to the difference between the time 
exploring the novel and the familiar object, corrected for total time exploring both objects. Two-
way ANOVA was used to compare the differences between MAM and SAL groups, drug 
treatment, and the possible interaction between MAM and treatment on behavioral measures. 
Tukey’s post-hoc comparisons were conducted for significant main effects.  
4.3 RESULTS 
4.3.1 Peripubertal Pomaglumetad Treatment Prevents Increased DA Neuron Population 
Activity in Adult MAM Rats 
Peripubertal (PD31-40) POM treatment significantly reduced DA neuron population 
activity in the VTA of rats recorded from PD 47-56  or “early adulthood” (Fig. 4-1 A; 2-way 
ANOVA main effects: for Treatment, F(2,38) = 4.801,  p = 0.014; post hoc VEH MAM vs POM 
MAM: p = 0.020) and from PD 83-96 or “late adulthood” (Fig. 4-1 D; 2-way ANOVA main 
effects: for MAM: F(1,35) = 17.29, p < 0.001, MAM-by-POM interaction: F(2,35)=4.518, p = 
0.018; post hoc VEH MAM vs POM MAM: p = 0.022). There was no significant difference in DA 
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significantly greater DA neuron population activity compared to VEH treated SAL rats (p = 
0.0138) and NI MAM rats displayed significantly greater DA neuron population activity compared 
to NI SAL rats (p = 0.020). There was no significant difference of peripubertal POM treatment in 
SAL rats in early (Fig 4-1 A) or late (Fig. 4-1 D) adulthood.  There was no significant difference 
in firing rate or percentage of spikes in burst of DA neurons in early adulthood (Fig 4-1 B-C) or 
late adulthood (Fig. 4-1 E-F). 
4.3.2 Reduced Novel Object Recognition Only in Adult MAM Rats That Did Not Receive 
Injections During Puberty 
No significant effects were observed in the NOR task in MAM or SAL rats across treatment 
groups, both in discrimination index (Fig. 4-2 A) and total time exploring the objects (Fig. 4-2 
B).  A main effect of MAM was observed in rats that were treated during puberty and tested 
in the NOR task during late adulthood (Fig 4-2 C; F(1,59) = 12.67, p < 0.001). Late adulthood 
MAM rats that received peripubertal POM treatment displayed significantly increased 
discrimination index compared to MAM rats that received NI during puberty (Fig 4-2 C; p = 
0.031), though it was not significantly different from MAM rats that received VEH during 
puberty (Fig 4-2 C). Late adulthood NI-MAM rats displayed significantly lower NOR compared 
to NI-SAL rats (p = 0.007), but VEH-MAM rats did not show a significant difference in NOR 
compared to VEH-SAL rats (Fig. 4-2 C). A main effect of treatment was observed in total 
time exploring objects in late adulthood (Fig. 4-2 D; 2-way ANOVA main effect for treatment: 
F(2,53) = 3.633, p = 0.0332.  
4-1 A) or late (Fig. 4-1 D) adulthood. In late adulthood, VEH treated MAM rats displayed
neuron population activity between VEH and No Injection (NI) in MAM or SAL rats in early (Fig. 
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compared to SAL rats that were treated with VEH or NI (Fig. 4-3 A; 2-way ANOVA main effects 
for: MAM: F(1,219) = 36.54, p < 0.001, MAM-by-POM interaction: F(2,219) = 5.782, p = 0.004; 
post hoc, MAM-VEH vs SAL VEH p < 0.001, MAM-NI vs SAL-NI p < 0.001). Peripubertal POM 
treatment in MAM rats significantly reduced the firing rate of pyramidal neurons in the vHPC 
compared to vHPC of VEH-treated MAM rats (p = 0.035) and NI-MAM rats (p = 0.001). There 
was no significant difference in the firing rate of vHPC pyramidal neurons between NI and VEH 
treatment in MAM rats and no significant difference in firing rate across all treatment groups in 
SAL rats (Fig 4-3 A). NI-MAM rat vHPC pyramidal neurons demonstrated significantly increased 
bursting activity compared to POM-MAM rats (p = 0.015) and there were no significant 
differences in bursting activity in SAL rats recorded during early adulthood (Fig 4-3 B). 
MAM rats that were treated with VEH or NI during puberty and recorded during late 
adulthood displayed significantly increased firing rate of pyramidal neurons in the vHPC 
compared to SAL rats that were treated with VEH or NI (Fig. 4-3 C; 2-way ANOVA main effects 
for: MAM: F(1,254) = 23.65, p < 0.001, MAM-by-POM interaction: F(2,254) = 3.678, p = 0.027; 
post hoc, MAM-VEH vs SAL VEH p = 0.002, MAM-NI vs SAL-NI p = 0.004). Peripubertal POM 
treatment in MAM rats significantly reduced the firing rate of pyramidal neurons in the vHPC 
compared to vHPC of VEH-treated MAM rats (p = 0.035) and NI-MAM rats (Fig. 4-3 C; p = 
0.001). No significant differences were observed in bursting activity in MAM or SAL rats recorded 
during late adulthood (Fig 4-3 D). 
 MAM rats that were treated with VEH or NI during puberty and recorded during early 
adulthood displayed significantly increased firing rate of pyramidal neurons in the vHPC 
4.3.3 Peripubertal Pomaglumetad Treatment Prevents Increased Firing Rate of Ventral  
          Hippocampal Pyramidal Neurons in Adult MAM Rats
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Figure 4-1: Peripubertal pomaglumetad treatment prevents increased DA neuron population activity in adult 
MAM rats 
(A) MAM and SAL rats were treated during puberty (PD 31-40) and electrophysiological recordings of DA neuron 
activity in the VTA were performed in early adulthood (PD 47-56). POM-treated MAM rats displayed reduced DA 
neuron population activity in the VTA compared to vehicle and and no injection-treated MAM rats. There were no 
significant differences in the firing rate (B) or bursting activity (C) of the DA neurons in MAM or SAL rats in early 
adulthood. (D) In rats that were treated during puberty (PD 31-40) and recorded in late adulthood (PD 83-96), POM-
treated MAM rats displayed reduced DA neuron population activity in the VTA compared to vehicle and and no 
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injection-treated MAM rats. There were no significant differences in the firing rate (E) or bursting activity (F) of the 
DA neurons in MAM or SAL rats in late adulthood. *p<0.05 **p<0.01 ***p<0.001 within groups #p<0.05 
##p<0.01 ###p<0.001 between groups. 
 
 
Figure 4-2: Reduced novel object recognition only in adult MAM rats that did not receive injections during 
puberty 
(A) In early adulthood (PD 47-48), MAM and SAL rats that were treated during puberty (PD 31-40) with POM, 
vehicle, or no injection, displayed no differences in time interacting with a novel object compared to a familiar 
object as measured by a discrimination index ((novel-familiar)/(novel+familiar)). (B) In early adulthood MAM and 
SAL rats treated during puberty, there were no significant differences in locomotor activity as measured by total 
time spent exploring the objects. (C) In rats that were treated during puberty and tested in late adulthood (PD 83-84), 
POM-treated MAM rats displayed an increase in time spent exploring the novel object as measured by the 
discrimination index compared to no injection-treated MAM rats, though not significantly reduced compared to 
vehicle-treated MAM rats. (D) No significant differences were observed in total time spent exploring the objects in 
 80 
MAM and SAL rats treated during puberty and tested in late adulthood.  *p<0.05 **p<0.01 ***p<0.001 within 
groups #p<0.05 ##p<0.01 ###p<0.001 between groups. 
 
 
Figure 4-3: Peripubertal pomaglumetad treatment prevents increased firing rate of ventral hippocampal 
pyramidal neurons in adult MAM rats 
(A) MAM and SAL rats were treated during puberty (PD 31-40) and electrophysiological recordings of the vHPC 
were performed in early adulthood (PD 47-56). Vehicle and no injection-treated MAM rats displayed increased 
firing rate of putative pyramidal neurons compared to vHPC pyramidal neuron firing rate in SAL rats, which was 
normalized in MAM rats that received POM treatment during puberty. (B) MAM rats that did not receive an 
injections during puberty showed a significant increase in percentage of spikes in bursts in early adulthood, which 
was not observed in MAM rats treated with POM during puberty. (C) Vehicle and no injection-MAM rats treated 
during puberty (PD 31-40) and recorded in late adulthood (PD 83-96) also displayed increased vHPC pyramidal 
neuron firing rate compared to vehicle and no injection-SAL rats. MAM rats treated with POM during puberty had 
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an average pyramidal neuron firing rate not significantly different from SAL rats. (D) No significnat differences in 
the percentage of spikes in burst in vHPC pyramidal neurons recorded in MAM and SAL rats at late adulthood. 
*p<0.05 **p<0.01 ***p<0.001 within groups #p<0.05 ##p<0.01 ###p<0.001 between groups.
4.4 DISCUSSION 
Although APDs alleviate positive symptoms in many patients with schizophrenia, they are 
hindered by adverse effects, limited efficacy, and high rates of treatment noncompliance (Kane et 
al., 1988; Fleischhacker et al., 1994; Conley and Buchanan, 1997; Lieberman et al., 2005). The 
overall poor functional outcome of many patients (Green et al., 2000) necessitates the development 
of improved treatment options. All current APDs produce their therapeutic effect by blocking the 
D2 receptor (Kapur and Remington, 2001) and there is an unmet need for different mechanisms of 
action for patients who do not respond to current treatments. One option is to target excitatory-
inhibitory dysfunction, which has been proposed to be a more central source of pathophysiology 
(Lewis et al., 2005; Lodge and Grace, 2011; Moghaddam and Javitt, 2012), upstream of DA 
dysfunction (Lodge and Grace, 2007). This dysfunction is observed during the prodromal period 
(Pantelis et al., 2007; Schobel et al., 2013; Allen et al., 2017), and it is also present in patients who 
are treatment non-responders (Demjaha et al., 2014; Mouchlianitis et al., 2015; Demjaha et al., 
2017). DUP is associated with worse functional outcome (Perkins et al., 2005), and so an ideal 
approach would be to target the neurophysiological processes that lead to psychosis as early as 
possible. 
Previous work in the lab has examined diazepam as a pharmacotherapy during the 
peripubertal period in the MAM model as a potential preventative treatment. Peripubertal 
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diazepam administration prevented increased activity in the amygdala, preserved PV+ 
interneurons in the HPC, and ultimately resulted in long lasting normalization of DA neuron 
activity in adult MAM rats (Du and Grace, 2013, 2016a, b). Benzodiazepines are generally not a 
practical option for long-term use as a preventative treatment for psychosis due to issues including 
tolerance and withdrawal effects (Busto et al., 1986; Longo and Johnson, 2000). However, it is an 
important proof-of-concept that targeting excitatory-inhibitory processes prior to the onset of DA 
dysfunction may improve long term outcomes.  
A promising drug target that has been shown to regulate glutamate release is the mGluR2/3 
(Conn and Pin, 1997). mGluR2/3 agonists have previously been investigated in clinical trials as a 
novel potential APD. The mGluR2/3 agonist, POM, was shown to be well tolerated and did not 
possess the side effects associated with current APD treatment, such as weight gain (Adams et al., 
2013). However, it was pulled from phase III clinical trials for lack of APD efficacy compared to 
current APDs (Stauffer et al., 2013; Adams et al., 2014; Marek, 2015). However, later analyses 
found that it was, in fact, effective in patients early in the disease, though not in patients who had 
schizophrenia for more than 10 years (Kinon et al., 2015). This finding indicated that further 
research on this mechanism of action, or other excitatory-inhibitory targets, is necessary. It also 
emphasized the importance of disease phase as a factor in clinical trials that can play a substantial 
role in heterogeneity of treatment response, whether due neurophysiological changes in the 
pathophysiology over time (Krystal and Anticevic, 2015) or other potential confounding variables, 
such as prior chronic APD treatment (Gill et al., 2014). Our previous work demonstrated that 
mGluR2/3 agonist POM can act in the vHPC to indirectly regulate DA neuron activity, likely by 
normalizing increased vHPC activity through its action on presynaptic receptors to negatively 
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modulate glutamate release (see Chapter 3). In this study, we examined its potential as a 
preventative treatment against DA system dysfunction in the MAM model. 
Peripubertal mGluR2/3 Agonist Administration Prevents HPC-DA Dysfunction in MAM Rats 
We found that peripubertal (PD 31-40) administration of POM prevented several of the 
adult phenotypes of the MAM model, including increased DA neuron population activity in the 
VTA and increased vHPC pyramidal neuron activity, potentially through preservation of vHPC 
PV+ interneurons. Previous studies have shown that the increased DA neuron population activity 
observed in adult MAM rats is indirectly driven by the vHPC, which shows increased pyramidal 
neuron firing rate in MAM rats, in addition to a loss in PV+ interneurons (Lodge and Grace, 2006b, 
2007; Lodge et al., 2009). Accordingly, treatments that reduce vHPC activity have been shown to 
reduce DA neuron activity in MAM rats (Gill et al., 2011; Gastambide et al., 2012; Perez and 
Lodge, 2013; Perez et al., 2013). 
These findings are consistent with clinical studies that have found increased glutamate, 
CBF, and CBV to be correlated with severity of psychotic symptoms conversion to psychosis in 
CHR patients (Harrison, 2004; Schobel et al., 2009; Allen et al., 2017). Severity of psychotic 
symptoms has been shown in other studies to correlate with measures of increased presynaptic DA 
function (Laruelle et al., 1999; Howes et al., 2011a), which is also shown to increase in individuals 
who transition to psychosis (Howes et al., 2011b; Egerton et al., 2013), and correlate with changes 
in HPC glutamate levels (Stone et al., 2010). Together, these studies fit a model in which increased 
HPC glutamate levels drive increased presynaptic DA function, leading to increased severity of 
psychotic symptoms. 
This leads to the question of how early intervention of the increased glutamatergic activity 
may produce long-lasting changes in preventing DA neuron hyperactivity. Puberty is a critical 
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time in the stabilization of PV+ interneuron connections within the HPC through the formation of 
PNNs, which is thought to underlie the closure of critical periods in development (Hensch, 2005; 
Cabungcal et al., 2013). Stress during puberty, particularly in those with a predisposition to 
increased stress responsivity, may lead to loss of PV+ neurons during this time and subsequent 
dysregulation of pyramidal neuron activity (Gomes et al., 2019a). MAM offspring display 
increased stress responsivity, prior to the manifestation of a hyperdopaminergic state (Moore et 
al., 2006; Zimmerman et al., 2013), which has led to the proposal that treatments aimed at reducing 
anxiety may prevent the deleterious effects of stress on the DA system during this critical time in 
development (Gomes et al., 2016). Increased limbic HPC drive, leading to local oxidative stress 
(Do et al., 2015), excitotoxicity (Plitman et al., 2014), and overall reduced adaptive functioning in 
related circuits, may create an accumulating pattern of circuit disruption that ultimately leads to 
psychosis through its downstream effects on the DA system. Intervening in the accumulation of 
glutamate dysfunction at these early stages (Schobel et al., 2013) may prevent further loss of PV+ 
interneurons during this period.  
The Role of Stress in Early Intervention for Psychosis 
mGluR2/3 agonists have been shown to have anxiolytic potential in both animal models 
and humans. They demonstrate anxiolytic-like activity in rodents in tasks including stress-induced 
hyperthermia and the elevated plus maze (Helton et al., 1998; Kłodzińska et al., 1999; Shekhar 
and Keim, 2000; Spooren et al., 2002; Linden et al., 2004). In humans, they have been shown to 
reduce fear-potentiated startle without sedative effects (Grillon et al., 2003) and demonstrated 
therapeutic potential for patients with panic disorder (Tizzano et al., 2002) and generalized anxiety 
disorder (Dunayevich et al., 2008). It is also of note that the effects observed in the present study 
were present even following the stress of repeated i.p. injections during puberty. Activation of 
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mGluR2/3 in the amygdala may play a role in its regulation of fear and anxiety states. Infusion of 
an mGluR2/3 agonist into the BLA disrupts fear-potentiated startle in rats. (Walker and Davis, 
2002). These results suggest that mGluR2/3 activation may in part suppress anxiety by inhibiting 
projection neurons within the BLA.  We have previously shown that POM can reduce DA neuron 
population activity in MAM rats through action in the vHPC. It would need to be confirmed 
whether it can reduce BLA activity similar to other mGluR2/3 agonists. If so, it would be 
interesting to determine whether its action in the BLA during peripubertal treatment is necessary 
for its long-term effects on DA neuron activity in adulthood, or whether reducing vHPC activity 
alone is sufficient.   
Potential Intermediate Phenotypes in the Neurodevelopment of the MAM Model 
MAM rats treated during puberty with VEH or NI and tested during early adulthood 
displayed increased firing rate of pyramidal neurons in the vHPC, but no reduction in NOR, as 
previously observed in adult MAM rats (Gomes and Grace, 2016). Additionally, their DA neuron 
population activity was not significantly different from VEH and NI-treated SAL rats recorded in 
early adulthood. However, MAM rats treated in the same cohorts and tested during late adulthood 
displayed both increased vHPC pyramidal neuron firing rates and increased DA neuron population 
activity. Only NI-MAM rats displayed reduced NOR in late adulthood, and all rats were handled 
equally, suggesting that repeated injections during puberty, regardless of POM or VEH, may 
improve NOR in adult MAM rats. Stress during puberty can produce mixed results on memory-
related behavior (Chaby et al., 2015b)and has been shown to result in greater adaptation to stressful 
experiences in adulthood, such as increased foraging behavior under threat (Chaby et al., 2015a), 
consistent with the concept of stress inoculation (Brockhurst et al., 2015; Meichenbaum, 2017). It 
is therefore possible that the mild stress of i.p. injections during puberty may have improved their 
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performance in the task. Overall, these results suggest that the late puberty/early adulthood period 
captured during PD 47-56 may have represented an intermediate phenotype in which the increased 
vHPC pyramidal neuron activity was present prior to increased DA neuron population activity, 
which emerged in late adulthood. It is unclear to what extent the transition to postpubertal MAM 
hyperactive DA system phenotype is sudden or gradual, though based on these results, it appears 
to follow the onset of increased vHPC pyramidal neuron activity. 
Overall, this study demonstrates that peripubertal administration of an mGluR2/3 agonist 
can produce long lasting effects in the MAM model, including normalizing vHPC pyramidal 
neuron activity and DA neuron population activity in the VTA. These results provide support for 
the potential of glutamatergic regulation as an early-stage preventative treatment against the 
emergence of DA dysfunction in schizophrenia.   
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5.0 GENERAL DISCUSSION 
Portions of Chapter 1 are adapted from: 
Sonnenschein, S. F., & Grace, A. A. (2019). Insights on current and novel antipsychotic 
mechanisms from the MAM model of schizophrenia. Neuropharmacology. doi: 
10.1016/j.neuropharm.2019.05.009. 
5.1 SUMMARY OF FINDINGS 
The studies described in this dissertation reveal state-dependent neuropharmacological 
effects in the regulation of DA neuron activity using the D2 partial agonist, ARI, and the mGluR2/3 
agonist, POM, highlighting the importance of using disease-relevant models in preclinical 
research. Additionally, we found that peripubertal administration of POM prevented the 
emergence of increased pyramidal neuron activity in the vHPC and increased DA neuron 
population activity in adult MAM rats, suggesting that mGluR2/3 may be a promising target as a 
preventative treatment against psychosis in patients. 
 In Chapter 2, we presented evidence that ARI administration reduces the number of 
spontaneously active DA neurons in MAM rats, which remained stable following 1-week 
withdrawal from repeated ARI administration, similar to previous observations following 
withdrawal from repeated D2 receptor antagonist treatment (Gill et al., 2014). However, unlike D2 
receptor antagonists (Valenti et al., 2011; Gill et al., 2014), neither acute nor repeated ARI 
administration showed an effect on DA neuron population activity in normal rats. Additionally, 
low doses of apomorphine either failed to restore, or further reduced, DA neuron population 
activity in MAM rats, suggesting that it did not act via depolarization block. ARI was also shown 
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to reverse depolarization block in haloperidol-treated MAM rats, resembling depolarization block 
reversal following low-dose DA agonist administration (Valenti et al., 2011), and consistent with 
distinct effects that are dependent on the state of the DA system. 
In Chapter 3, we demonstrated that POM could dose-dependently reduce DA neuron 
population activity in MAM rats and that intra-vHPC infusion of POM was sufficient to produce 
this effect. POM also increased novel object recognition in MAM rats and blocked stress-induced 
increases in DA neuron population activity in normal rats. However, these effects were only 
observed in conditions with increased vHPC activity, such as in MAM rats, or following restraint 
stress, but they were not observed in normal rats or baseline conditions, consistent with previous 
studies demonstrating no effect of mGluR2/3 agonists on DA levels in normal rats (Verma and 
Moghaddam, 1998; Pehrson and Moghaddam, 2010). This study reveals a novel role of mGluR2/3 
agonists in the regulation of DA neuron activity that may contribute to its potential therapeutic 
effects. Once again, distinct effects were observed in a hyperdopaminergic vs baseline state; 
however, in contrast to ARI, the state-dependent effects of POM on DA system regulation 
appeared to require the presence of increased vHPC activity.   
In Chapter 4, we found that MAM rats treated with POM during puberty (PD 31-40) 
demonstrated normalized DA neuron activity and vHPC pyramidal neuron activity when examined 
at early and late adulthood timepoints. In early adulthood, control MAM rats demonstrated 
significantly increased pyramidal neuron activity in the vHPC, but no main effect of MAM on DA 
neuron activity or novel object recognition. This may represent an intermediate-phenotype in 
neurodevelopment of the MAM model; however, even at this timepoint, the pyramidal neurons in 
the vHPC showed increased firing rate that was normalized by peripubertal POM treatment. No 
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significant effects of treatment were observed in SAL rats at any time point or experimental assay, 
consistent with previous observations that the effects of POM are state-dependent.  
5.2 TECHNICAL CONSIDERATIONS 
5.2.1 Anesthesia 
All of the electrophysiological recordings described were performed with chloral hydrate 
anesthesia. Anesthesia inevitably alters neural activity compared to an awake/behaving state, 
particularly in brain regions related to arousal and cognition (Brown et al., 2011). Chloral hydrate 
was used in these experiments due to its minimal effects on DA neuron firing properties compared 
to the awake state (Bunney and Grace, 1978; Chiodo and Bunney, 1985). Its extensive use in 
similar studies of DA neuron activity in the VTA , in addition to its use in the recordings of other 
brain regions, including the BLA (Rosenkranz and Grace, 2001, 2002; Du and Grace, 2016b), 
mPFC (Lavin et al., 2005), thalamus (Lavin and Grace, 1998; Zimmerman and Grace, 2018), 
ventral pallidum (Lavin and Grace, 1998), NAc (Belujon and Grace, 2014), and HPC (Lodge and 
Grace, 2007), allows for comparison between studies. Nonetheless, it cannot be assumed to be 
equivalent to neural activity in the awake state and results must be interpreted with this in mind. 
5.2.2 Depolarization Block 
Depolarization block has been observed across numerous studies in rats, but questions 
remain about the consistency and consequences of the phenomenon. Some have argued that it may 
be an artifact of anesthesia (Mereu et al., 1995; Melis et al., 1998). However, chloral hydrate, the 
anesthesia used for DA neuron recordings, normally blunts the excitatory response of DA neurons 
 90 
to APDs (Bunney et al., 1973) and depolarization block has been observed in nonanesthetized, 
paralyzed rats (Bunney and Grace, 1978; Chiodo and Bunney, 1985). There have also been 
inconsistencies in the effect of depolarization block on striatal DA release. Some have reported a 
reduction in basal DA release that corresponds with depolarization block (Blaha and Lane, 1987; 
Lane and Blaha, 1987; Moore et al., 1998), whereas others have not found a difference in striatal 
DA levels (Ichikawa and Meltzer, 1991; Moghaddam and Bunney, 1993). However, the lesion 
produced from microdialysis probe insertion was later found to disrupt depolarization block, and 
the issue can be avoided by implanting the microdialysis probe prior to APD administration 
(Moore et al., 1998). The long-term changes to DA neuron activity following APD withdrawal are 
also unclear and require further investigation. DA neuron activity remains reduced for at least a 
week following repeated D2 antagonist administration in both MAM and SAL rats. However, 
population activity is no longer restored with administration of a DA agonist in MAM rats (Gill et 
al., 2014). This finding requires replication, but suggests that the reduction following withdrawal 
may no longer be caused by depolarization block and may be due to other compensatory 
mechanisms. 
5.2.3 Neuronal Criteria for Identification 
The cells identified as DA neurons were based on established criteria involving factors 
such as waveform and firing rate (Grace and Bunney, 1983; Grace and Bunney, 1984; Ungless and 
Grace, 2012). The VTA contains approximately 70% DA neurons, 30% GABA interneurons, and 
a small percentage of glutamatergic neurons (Yamaguchi et al., 2007; Nair-Roberts et al., 2008). 
There is heterogeneity even within the tyrosine hydroxylase+ neurons in the VTA, such as neurons 
that corelease DA and glutamate (Stuber et al., 2010). However, the vast majority of DA neurons 
can be reliably identified using the established electrophysiological criteria, and the large number 
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of DA neurons sampled across the 6-9 tracks limits the impact of any potential misidentifications 
(Ungless and Grace, 2012).  
We observed greater electrophysiological diversity in the vHPC compared to the VTA, 
consistent with the wide variety of cell subtypes and wide range of electrophysiological properties 
previously identified (Scharfman, 1992; Parra et al., 1998). The lack of established, specific 
criteria for pyramidal neurons in the vSub under anesthesia was a limitation in the 
electrophysiological analysis. However, putative pyramidal neurons were identified strictly by the 
criteria described in Chapter 4, which was based on previous vHPC recording performed in the lab 
(Lodge and Grace, 2007). Further research is necessary to confirm specific electrophysiological 
criteria for the identification of neuronal subpopulations in the HPC.  
5.2.4 Drug Administration 
Drug dosage and administration methods are critical factors in demonstrating consistent 
effects, both when comparing between animal studies and translating between animal and human 
research. Metabolic differences must be considered to determine corresponding receptor 
occupancy (Kapur et al., 2003) in addition to the administration method, particularly when looking 
at the effects of repeated treatment.  For example, transient APD delivery has been found to be 
more effective than continuous D2 blockade, which was more likely to result in D2 receptor 
upregulation and behavioral tolerance. It has been reported that continuous administration may be 
more likely to result in DA supersensitivity (Samaha et al., 2008), whereas intermittent dosing 
with “drug holidays” is more likely to maintain efficacy (Remington and Kapur, 2010). Receptor 
expression was not investigated in these studies, though it could be included in future studies to 
examine potential receptor upregulation or downregulation. Ideally, drug doses should be based 
on in vivo receptor occupancy levels, which can improve translation between human and animal 
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studies (Kapur et al., 2003; Remington and Kapur, 2010). The drug doses used in these 
experiments were based on dosages used in prior research, though future research should examine 
changes in receptor expression and receptor occupancy for improved translatability.  
5.3 FUTURE DIRECTIONS AND IMPLICATIONS FOR THE TREATMENT OF 
SCHIZOPHRENIA 
5.3.1 Animal Model Selection and Interpretation in Preclinical Research 
Normal animals are useful as a blank slate to examine the effects of a drug, but they are 
not well-suited for APD screening compared to models that incorporate disease-relevant 
abnormalities. For example, D2 antagonists and D2 partial agonists function differently in a 
hyperdopaminergic state, as observed in the MAM model of schizophrenia, which may be more 
representative of their actions in a patient (Valenti et al., 2011b; Sonnenschein et al., 2019). 
State-dependent differences in electrophysiological and behavioral measures were also observed 
with mGluR2/3 administration. Effects were observed in the presence of vHPC hyperactivity, but 
not under normal conditions. Similarly, state-dependent differences on DA neuron population 
activity have been observed with the administration of a PAM of the α5 subunit of GABAA 
receptors (Gill et al., 2011) and may be relevant for other compounds, particularly those that act 
as modulators to target excitatory-inhibitory processes.  
The choice of proper animal models and assays to study APDs is particularly important 
when testing novel mechanisms. There has been much debate over whether current preclinical 
assays of APD efficacy are useful for screening novel mechanisms of action (Carpenter and 
Koenig, 2008; Nestler and Hyman, 2010). For example, blockade of amphetamine-induced  
hyperlocomotion is a behavioral task in rodents commonly used to predict APD efficacy to 
treatpositive symptoms. However, amphetamine-induced hyperlocomotion is believed to arise 
from a ventromedial limbic striatal action (Creese and Iversen, 1975), whereas imaging studies 
show that increased raclopride displacement and increased f-DOPA uptake that correlate with 
psychosis is present primarily in the associative striatum (Kegeles et al., 2010; Kesby et al., 
2018). A more effective screen might selectively target DA release in the associative striatum, 
such as a task that addresses the role of DA function in salience attribution and selective 
attention, which may be a more reliable measure of APD efficacy.  
5.3.2 Treatment History 
It has long been suggested that neuroadaptations to chronically administered psychiatric 
drugs can produce discontinuation syndromes and facilitate relapse, with rapid withdrawal 
inducing more severe relapse (Viguera et al., 1997). Given that patients typically receive long-
term APD treatment, animal research would benefit from implementing more chronic 
treatment studies to examine long-term responses and identify any compensatory mechanisms, 
including changes in receptor response and more wide scale changes in circuit plasticity. 
One of the consequences of chronic D2 antagonist treatment is D2 receptor upregulation 
(Silvestri et al., 2000; Samaha et al., 2007), which can produce a state referred to as DA 
supersensitivity (Chouinard et al., 2017). Development of DA supersensitivity has been 
attributed to breakthrough symptoms and the rapid rate of relapse following APD discontinuation 
or dose reduction, which often results in new and more severe symptoms (Chouinard and Jones, 
1980; Chouinard et al., 2017). Studies in rats have demonstrated that DA supersensitivity occurs 
both during and after treatment, potentially accounting for breakthrough symptoms, although the 
consequences are more apparent following withdrawal (Samaha et al., 2007). Some have argued
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that breakthrough symptoms are more likely due to treatment noncompliance and can be 
circumvented by continuous drug blood levels usinglong acting injectables (Correll et al., 2018). 
Long-term treatment with long acting injectable APDs has been shown to reduce the rate of 
relapse compared to oral administration in randomized controlled trials (Kishimoto et al., 
2012), but still roughly 20% of patients treated with long acting injectable APDs relapse within 
a year (Leucht et al., 2011). (Murray et al., 2016). Despite the increase in D2 receptors, less 
therapeutic tolerance occurs to APDs in a clinical setting than what would be expected from 
antagonism of a receptor, which may be due to the indirect method of DA neuron regulation (i.e. 
depolarization block); however, the reduction of DA neuron activity is far from returning the 
system to a normal state. Further research on the interrelated topics of APD tolerance, 
withdrawal, and relapse is critical for clear guidelines on switching between APDs and 
determining which patients would benefit from dose reduction following stabilization.  
Under current clinical trial protocols, switching from one D2 antagonist to another may 
not appear to be a critical issue. However, when testing novel target compounds, prior 
treatment history may significantly impact the results. While the washout period typically used 
in clinical studies may be adequate to decrease blood levels of the APD, a short withdrawal 
period is not sufficient to reverse the effects of the drug on the DA system (Gill et al., 2014). It 
also raises the possibility that DA supersensitivity following prior D2 antagonist treatment 
in patients with schizophrenia may mask potential effects of novel target compounds in clinical 
trials, despite their promise in screening assays performed in normal, drug-naïve rodents. The 
results of the trial could, therefore, be potentially confounded by the long-lasting changes in 
the system made by the presence of the APD. Such a confound may contribute to why POM 
performed better in early-in-disease patients (Kinon et al., 2015). In the presence of D2 receptor 
upregulation following chronic D2 receptor antagonist treatment (Silvestri et al., 2000; Samaha
95 
et al., 2007), it is possible that only another D2 receptor-targeting drug may be effective in 
reversing hyperresponsivity to DA. However, evidence suggests that D2 partial agonists, 
such as ARI, do not induce DA supersensitivity (Tadokoro et al., 2011; Amada et 
al., 2019). Thus, testing novel compounds on patients who are withdrawn from ARI, 
drug-naïve, or confirmed to be non-compliant with their prior medication may be more 
effective strategies in identifying therapeutic value. The effects of prior APD treatment, and 
other changes to the brain that are not represented in normal or drug-naïve rats, must be 
considered in the development of novel drugs. 
5.3.3 Improved Treatments for Psychosis 
Future development of APDs should aim to provide normal regulation of DA neuron 
activity rather than general suppression of DA neurotransmission. Given the 
accumulating evidence that loss of PV + interneuron regulation of pyramidal cell activity 
underlies many aspects of schizophrenia, including its role in DA system hyperactivity (Benes 
and Berretta, 2001; Lodge and Grace, 2007; Lodge et al., 2009; Lewis et al., 2012), 
GABAergic and glutamatergic targets still hold promise as an effective therapy. Moreover, 
targeting excitatory-inhibitory processes may avoid consequences associated with D2 
antagonist treatment and may also alleviate more symptoms of the disorder, including 
negative and cognitive symptoms (Fig. 5-1 A-B), which often precede FEP and persist after 
treatment of psychotic symptoms (Harvey et al., 2005). In particular, compounds that can 
regulate HPC activity, such as mGluR2/3 agonists, have the potential to treat dysfunction 
upstream of DA dysregulation. Additionally, it is important to determine whether novel target 
compounds are effective in patients that are treatment resistant to current APDs. Compounds 
such as mGluR2/3 agonists may be effective in treating symptoms in patients who do not 
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Interventions that directly target the pathophysiological processes that cause psychosis also 
have the potential to modify its progression. APD treatment does not normally begin until FEP at 
the earliest. However, given that longer DUP is associated with worse outcome and greater 
structural and functional deficits (Perkins et al., 2005; Lappin et al., 2006; Sarpal et al., 2017; Goff 
et al., 2018), it suggests that treatment/prevention of psychotic symptoms may be able to influence 
the course of the disease. Preventative interventions may provide greater and/or more long-lasting 
benefits than treating psychotic symptoms once they progressed beyond the CHR state.  
In support of preventative treatments, interventions administered during adolescence can 
reduce the expression of schizophrenia-related anomalies in adult rodents (Du and Grace, 2013, 
2016a, b). We propose that MAM rats are not “doomed from the womb”, but instead fit a “two hit 
model” where the early disruption in brain development leads to heightened vulnerability to stress, 
with the potential for intervention prior to the second hit. The HPC is of particular interest as a 
treatment target because PV+ interneurons in the HPC continue to mature through late adolescence 
(Caballero et al., 2013) and the HPC is highly susceptible to stress (Sapolsky, 1985; Sapolsky et 
al., 1990). Therefore, severe stress or heightened stress responsivity during adolescence may 
damage the development of the vulnerable PV+ interneurons, leading to impaired DA system 
function that may reciprocally impact stress (Gomes and Grace, 2016; Gomes et al., 2019a). 
Interestingly, it is specifically distressing psychotic-like experiences in adolescence that are most 
indicative of CHR state, greater risk of developing a psychotic disorder (Kline et al., 2014), and 
reduced functional connectivity in cognitive networks (Karcher et al., 2019). Therefore, treatments 
that reduce stress, or more specifically, protect PV+ interneurons, may be particularly effective 
when administered during adolescence.   
respond to current D2 targeting APDs, but still show increased glutamate levels (Demjaha et al., 
2012; Demjaha et al., 2014).  
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Safe and effective interventions in at-risk populations require more reliable strategies for 
estimating the risk of conversion in CHR individuals, which may also provide insight into potential 
targets for course-altering medication. Multi-modal strategies have been the focus of a number of 
recent studies, such as the incorporation of different types of neuroimaging techniques, 
neurocognitive batteries, neurophysiological assessments, and polygenetic risk models (Koike et 
al., 2013; Cooper et al., 2014). There is also potential in the use of machine learning to process 
patterns of data from multi-modal techniques (Pettersson-Yeo et al., 2013). Many of these studies 
aim to find sub-categories of CHR individuals based on neurobiological biomarkers to reduce 
heterogeneity and improve clinical trial targeting. In the case of FEP, it is also crucial to develop 
more reliable tools to predict whether a patient will or will not respond to DA blockade, so that 
alternative approaches (e.g. mGluR2/3-targeting drugs) may be implemented as early as possible. 
Neuromelanin-sensitive MRI, which provides a noninvasive measure of neuromelanin as a 
measure of DA metabolism, is a method that has shown early promise as one such assay that could 
be useful for identification of potential treatment-resistant patients (Wengler et al., 2019).  Further 
research is needed to accurately differentiate and predict the varying trajectories of CHR 
individuals.  
The uncertainty and ethical concerns of a prodromal diagnosis limits the confidence in 
early intervention (Patel et al., 2014). Responsible implementation of preventative treatment 
requires accurate prediction of the risk of transition with as few false positives as possible to 
prevent stigma, unnecessary treatment, and related adverse effects. Additionally, not all psychotic 
patients progress to a chronic psychotic disorder and some will convert to an affective disorder 
(Bromet et al., 2011). Future research directions include: strategies to better predict risk of 
conversion in CHR individuals, finding reliable biomarkers to predict disease course and treatment 
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response, and determining which therapeutic strategies would be most effective for 
preventing/minimizing psychotic symptoms. Through the pursuit of these questions, it may 
eventually be possible to prevent the progression of psychosis with early intervention in 
schizophrenia and related disorders. 
5.4 CONCLUDING REMARKS 
The therapeutic value of current APDs is hindered by numerous side effects and 
limited efficacy across symptom domains, which can lead to a lifetime of maintenance 
treatment (Lieberman et al., 2005; Leucht et al., 2012). Current APDs are also unable 
to address heterogeneity, both between individuals with distinct pathologies (Demjaha et al., 
2014; Howes and Kapur, 2014) and within an individual through different phases of the 
disease (Krystal and Anticevic, 2015). Novel pharmacological targets have been investigated 
based on theories largely generated from animal research, yet clinical trial results have been 
less than promising (Dunlop and Brandon, 2015). The apparent lack of predictive validity, as 
evidenced by the failed clinical trials, necessitates reevaluation of the rigor and design of 
preclinical research for the future development of novel therapies. Similarly, clinical trial 
design should be re-evaluated based on data emerging from preclinical studies. Current efforts 
must be aimed at investigating potential variables that contribute to this disconnect to improve 
the translation of animal models and the therapeutic value of pharmaceutical treatments.  
The mechanisms of action tested in the clinical trials of mGluR2/3 agonists were derived 
from decades of human and animal model research showing excitatory-inhibitory imbalance as a 
core component of schizophrenia and a promising target across symptom domains. Their failure 
created uncertainty in the current theoretical framework of schizophrenia regarding the potential  
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to treat glutamatergic dysfunction. Moving forward, one option is to leave these mechanisms 
ofaction in the “pharmaceutical graveyard” and forgo the pursuit of similar novel target 
compounds for the treatment of schizophrenia. Alternatively, we propose that these drugs, or 
others based on similar theoretical concepts, still hold promise, but require additional preclinical 
screening to better conduct clinical trials.  
Animal research has provided critical insight into the mechanisms of action of current 
APDs and a framework to test hypotheses about the neurobiology underlying schizophrenia. 
Studies performed in the MAM model have demonstrated the importance of studying the effects 
of APDs on a system representative of patients. The hyperdopaminergic system in MAM rats 
shows rapid onset of depolarization block to D2 antagonists and responds to D2 partial agonists 
through a manner distinct from depolarization block (Valenti et al., 2011b; Sonnenschein et al., 
2019), as discussed in Chapter 2. These findings are consistent with clinical results and not 
observed in normal rats. We also propose that therapeutic strategies should be directed on upstream 
regulation of DA neurons, such as the indirect regulation of DA neuron activity through the use of 
mGluR2/3 agonists, as discussed in Chapter 3. The MAM model also has shown that 
pharmacological methods can be used to prevent full emergence the HPC-VTA dysfunction in 
adulthood (Du and Grace, 2013, 2016a, b), as observed following peripubertal mGluR2/3 agonist 
administration, discussed in Chapter 4. These findings support the potential of targeting 
glutamatergic dysfunction early in the disease to alleviate symptoms and potentially prevent 
conversion of psychosis.  
The failure of recent novel target drugs does not invalidate the theory behind their 
development, but highlights the gaps that exist in their translation. Animal models are best applied 
in collaboration with studies performed in patients to find parallels and test predictions. 
Representative animal models, informed by clinical studies, can then be used to investigate the 
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contribution of variables that underlie patient heterogeneity. These findings must then be 
incorporated into the design of clinical trials of novel target compounds, or else promising targets 
may be abandoned despite great potential to improve treatment options for schizophrenia. 
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